
Oryx International Growth Fund Limited

Annual Report and Financial Statements for the year ended 31 March 2023



Index

	Page
Strategic Report	
Company Overview	1
Chairman's Statement	2
Investment Manager's Report	3
Ten Largest Holdings	5
Investment Schedule	8
Directors' Report	17
Corporate Governance Report	22
Audit Committee Report	33
Directors' Remuneration Report	37
Statement of Directors' Responsibilities	39
Independent Auditor's Report	41
Statement of Comprehensive Income	50
Statement of Financial Position	51
Statement of Changes in Equity	52
Statement of Cash Flows	53
Notes to the Financial Statements	54
Alternative Performance Measures	73
Company Information	Inside back cover

Strategic Report Company Overview

Key Figures

(£ in millions, except per share data)	At 31 March 2023	At 31 March 2022
Net Asset Value ("NAV") attributable to shareholders		
- Ordinary Shares	206.43	219.41
Investments	193.04	208.89
Cash and cash equivalents	15.59	10.62
NAV per share attributable to shareholders		
- Ordinary Shares	14.75	15.67
Share Price	11.95	14.80
Discount to NAV	(18.98%)	(5.55%)
Loss per share	(0.93)	(0.75)

Strategic Report Chairman's Statement

2023 was a difficult year with the well trailed problems of the world impacting on the investment world. In the light of this background, while the overall decline in NAV amounted to 5.91%, all of this took place in the first half of the year where a decline of 14.61% was reported, the second half saw a gain of 9.76%. This recovery goes to the heart of our investment philosophy which is only to invest in companies which offer good value, have strong balance sheets and prospects that can be unlocked through active management. I am also pleased to report that this momentum has continued into this year with a further increase in net assets of 4.88% being recorded at the end of May. It is also worth noting that in the three years to 31st March, our NAV grew by 68% and over a ten year period by 297%.

During the Company's lifetime, the Board has often been faced with the question of where our next opportunities are going to be found. As you can see from the Investment Manager's report below, the year under review has seen some successful disposals with our cash position increasing by £5m to £15.5m during the course of the year. But, as is also pointed out in the same report, periods of financial stress throw up opportunities and it will allow investments to be found at more reasonable valuations thereby offering rewards for the future.

During the course of the year, we saw both Rupert Evans and Waleed Chatila retire from the board. Rupert, a leading lawyer in Guernsey, served from the Company's founding in 1996 and his years of wise advice were much appreciated and will be missed. Likewise, Waleed, who also chaired our Audit Committee, contributed over 19 years of service with his broad knowledge of both the commercial and investment world. I would like to record the sincere thanks of both the Board and the shareholders for their contribution to the long-term success of the business. I am also pleased to welcome to the Board,

Gavin Farrell, again a leading Guernsey lawyer and Jamie Brooke, an acknowledged investor in small companies.

In line with our stated policy, the Board do not intend to pay a dividend. It is difficult to predict any particular outcome particularly with the constant drip of uncertainty and unwelcome economic news. However, on one matter I am convinced and that is quality will win in the long term. Christopher Mills and the team surrounding him at Harwood have demonstrated that the strategy of investing in good companies with excellent prospects will deliver strong long-term rewards and with that in mind, we look forward to the future with confidence.

Nigel Cayzer Chairman 5 July 2023

Strategic Report Investment Manager's Report

The Company's NAV declined by 5.9% in a year where our comparative indices fell by 19% on average in a difficult year for UK small cap equities.

Global markets faced continued turbulence, with interest rates facing additional raises to counter high inflation. Though several leading inflationary indicators have reduced in recent months, wage inflation remains steady and continues to burden businesses with higher costs. The war in Ukraine continues, with a counter offensive reportedly underway but no clarity on a near term ceasefire. The banking sector saw disruption not seen since the global financial crisis as Silicon Valley Bank collapsed as a result of a bank run on deposits. This sparked a collapse in share prices across US regional banks and most shockingly, the demise of Credit Suisse, which was subsequently acquired by UBS in a Swiss government supported rescue.

Mortgage rates have continued to climb, suppressing demand in the housing sector and curtailing construction by house builders. Energy prices climbed significantly during the year but have since reduced as the energy cap comes down. International pension schemes have reduced exposure to UK equities and mutual funds faced continued outflows, putting pressure on share prices.

Overall, 2022 was a difficult year for the UK and global equity markets. While there is reason for pessimism, the outflow of capital from UK small caps has provided our Company with ample opportunity to acquire significant stakes in companies at discounted values. Several large and small UK public companies were subject to take over bids during the course of the year, with particular interest arriving from overseas buyers looking to take advantage of suppressed valuations. Importantly, some of our significant holdings were subject to bids during the

year, providing the Company with ample liquidity for 2023 and beyond as detailed below.

Quoted equities:

The 2022 financial year saw several of our core positions being subjected to takeover bids, with the offer for Sureserve Plc arriving after the March year end. Crestchic Plc received a bid from Aggreko, generating a 139% return on our initial investment and circa £12 million in cash returned to the Company. The Sureserve bid at 125p marks a 268% return on initial investment and 50.6% year on year, returning £12.5 million to the Company. Curtis Banks Plc received an offer of 350p from Nucleus Financial group, while two of our smaller holdings Fulham Shore Plc and Seraphine Plc were also bid for. Lastly, Smoove Plc has received interest from Australia based PEXA for an unspecified amount, causing the shares to gain 39% upon announcement. Taken together, the above transactions will provide (pending completion) circa £40 million of cash to deploy in future investments.

Niox Group Plc and Kitwave Group Plc were standout performers in the year and have continued to outperform the market since our March year end. The position in Kitwave Group, a wholesale distribution business that engages in value accretive bolt on M&A, was built in the prior year so we are pleased with the good performance of the business thus far. The management team at Niox Group Plc have delivered on their cost reduction targets, with the process now complete and the focus now on growing sales in the US and Asia.

The underperformers among our significant holdings were Hargreaves Services Plc, EKF Diagnostics and Tribal Group. Hargreaves Services had previously enjoyed a year of 'super profits' from its German JV business as pig iron and zinc prices skyrocketed and while those have started to come down, the rest of the business has performed well. The net asset value

Investment Adviser's Report (continued)

of the business is, we believe, in excess of £6.05 per share, well above the current share price and we believe that this delta will narrow in the short to midterm as investors better understand the true value of the business. EKF completed a write down of its Covid-19 related assets and the previous CEO, Julian Baines, has been reinstalled to consolidate the cost base and drive revenue growth in the core business. Tribal Plc lost a major contract with Singapore based NTU and the shares were punished accordingly. We have increased our holding in the business from 8.25 million shares to 20 million shares at the reduced price to right size our cost base. We believe the value of Tribal's remaining business and IP offers material upside from the current valuation.

Over the course of the year we have increased our stake in Carr's Group from 1.1 million shares to 5 million shares, making it a top ten holding in the portfolio. We added positions in Hostmore Plc, Pendragon Plc, Spire Healthcare Plc, Smoove Plc and OnTheMarket Plc, all of which are attractive assets for acquisition to a larger competitor (Smoove received an unspecified bid approach as earlier noted). Our holding in Kitwave Plc was reduced to 2.25 million shares from 4 million shares as the share price doubled over the period.

Unquoted equities:

Antler Holdco was sold during the year as a small part of the holding in Moxico. Two companies delisted, Source Bioscience and GYG, as the cost of remaining a public company was not consistent with the benefits.

Outlook:

At our year end March 2023, several of the global economic issues highlighted in our last annual report remain. Interest rates sit at 4.5% but the UK market is currently discounting additional raises up to 100bps by the end of 2023. The war in Ukraine rages on and China has made disturbing motions towards Taiwan, though has not materialised into a serious concern as it stands. Despite that backdrop, energy prices have started to fall and sea freight costs have normalised to under \$2000 per container, stimulating the global supply chain. The rise of artificial intelligence in the consumer environment (though still in its infancy) marks the potential for sea change in operational efficiencies for a broad range of industries.

Our value orientated strategy should benefit from the suppressed valuations in the UK market. High interest rates have punished those that rely on high amounts of leverage for growth, dragging the overall market down with them. As can be seen in our top ten holdings listed below, we have continued to target companies with a high level of cash generating ability alongside existing healthy balance sheets that are better suited to navigate a difficult macro environment.

Harwood Capital Management (Gibraltar) Limited 5 July 2023

Strategic Report Ten Largest Holdings

	As at 31 March 2023			11.18	As at 31 March 2022			
	Holding Units	Cost	Fair Value	% of NAV	Holding Units	Cost	Fair Value	% of NAV
Niox Group plc	40,000,000	7,715,505	17,680,000	8.56%	40,000,000	7,715,505	14,400,000	6.56%
Centaur Media Plc	35,000,000	12,166,100	16,800,000	8.14%	35,000,000	12,166,100	16,100,000	7.34%
Avingtrans Plc	4,000,000	10,785,350	16,400,000	7.94%	4,000,000	10,785,350	18,600,000	8.48%
Curtis Banks Group Plc	4,225,000	9,717,500	14,322,750	6.94%	4,225,000	9,717,500	10,985,000	5.01%
Redcentric Plc	9,500,000	8,883,066	12,635,000	6.12%	9,500,000	8,883,066	10,687,500	4.87%
Ekf Diagnostics Holdings Plc	36,000,000	4,866,592	11,124,000	5.39%	35,362,500	4,690,119	15,276,600	6.96%
Hargreaves Services Plc	2,450,000	7,912,696	10,216,500	4.95%	2,450,000	7,912,696	13,818,000	6.30%
Sureserve Group plc	10,000,000	3,376,149	8,500,000	4.12%	10,000,000	3,376,149	8,100,000	3.69%
Tribal Group Plc	20,000,000	11,603,585	7,840,000	3.80%	8,250,000	6,727,335	7,012,500	3.20%
Carr's Group Plc	5,000,000	5,521,950	6,400,000	3.10%	1,100,000	1,674,775	1,650,000	0.75%

NIOX Group Plc

Cost £7,715,505 (40,000,000 shares)
Market value £17,680,000 representing 8.56%
of NAV

Niox Group Plc is a commercial-stage specialty pharmaceutical company focused on respiratory diseases. Its gold standard core NIOX product provides a diagnostic FeNO test in asthma to international markets.

The company's management team completed its cost reduction program in 2022, delivering £7.7 million of EBITDA versus a forecasted £4.1 million. Revenue growth was impressive despite China being hampered by Covid-19 related lock downs and will be boosted by restrictive measures now being relaxed. The distributor led sales model in the US will drive faster growth going forward, selling into both primary and secondary care physicians. The balance sheet is robust with circa £18.4 million net cash anticipated to grow to £26 million by year end 2023. The recent share price performance has been strong.

Centaur Media Plc

Cost £12,166,100 (35,000,000 shares)

Market value £16,800,000 representing 8.14%

of NAV

Centaur Media is an international provider of business information, training, and specialist consultancy across its Xeim and The Lawyer business units. The company is actively engaged in the marketing and legal sectors, offering a wide range of products that add value to their customer base.

The company paid two special dividends over the period, reducing net cash from £16 million to £7.1 million. The decision was facilitated by the high cash generation attributes of the business combined with a limited need for capital expenditure.

Management have continued to drive profit margins higher and are targeting a 23% EBITDA margin in 2023, a 260bps improvement from the prior year. The company trades at a significant discount to its intrinsic value and this gap should close as management continue to improve the overall quality of the business.

Ten Largest Holdings (continued)

Avingtrans Plc

Cost £10,785,350 (4,000,000 shares)

Market value £16,400,000 representing 7.94%

of NAV

Avingtrans is a buy and build strategy business that operated in the engineering markets. The company's self-branded 'Pinpoint - Invest - Exit' (PIE) has consistently delivered high returns for shareholders and the current portfolio contains some high value assets which are supported by further investment in the medical and industrial imaging space.

The company has maintained a stable balance sheet (£17.3 million net cash vs £16.7 million YoY) despite inflationary pressure and supply chain instability while continuing to invest in its Magentica and Adaptix assets. Third party investment into these two assets implies a valuation at circa £50 million, a significant uplift from prior year. The share price softened in the year despite management hitting their targets. The EPM segment performed well during the year, growing sales by 16% while PSRE was flat on the year. The current market capitalisation of the business is £130 million with the combined assets estimated at over £200 million on industry comparables, implying significant upside.

Curtis Banks Group Plc

Cost £9,717,500 (4,225,000 shares)

Market value £14,322,750 representing 6.94%
of NAV

Curtis Banks Group is engaged in the provision of pension administration services, primarily for self-invested personal pension schemes (SIPPs). It is one of the largest providers in the United Kingdom with circa £37.4 billion of assets under management.

The company received a bid from Nucleus Financial Plans on January 6th 2023 for 350p per share, providing a circa 52% return for the Company on initial investment with the deal still being finalised.

Redcentric Plc

Cost £8,883,066 (9,500,000 shares)

Market value £12,635,000 representing 6.12%
of NAV

The company is a leading UK IT managed services business that provides IT and cloud services to meet its customer and client's needs. The group benefits from an established reputation as an end-to-end managed service provider delivering innovative technology to improve business productivity and efficiency.

The company completed several bolt on acquisitions during the period, driving top line sales from £90 million to £150 million at their 2022 year end. The acquisitions improve the quality of sales by increasing the concentration of their complex cloud, cyber and collaboration services from 56% to 65%. Management have continued to reduce costs, with £9.7 million removed during the year and an additional £7 million of cost savings targeted.

The company is one of the few in our top ten with net debt on the balance sheet (circa £39.3 million) but improved profitability and a £100 million debt facility provide ample liquidity for its working capital requirements in the next phase of its growth.

EKF Diagnostics Holdings Plc

Cost £4,866,592 (36,000,000 shares)

Market value £11,124,000 representing 5.39%

of NAV

EKF Diagnostics is a global integrated market leader in the medical diagnostics business, offering a large range of hemoglobin and hematocrit point of care tests. The business also has a clinical laboratory division where its liquid reagents can be used widely in analysers found in hospital laboratories.

The company wrote down its Covid-19 related assets during the period, disposing of the laboratory

Ten Largest Holdings (continued)

diagnostics business and closing down the UK contract manufacturing business. The former CEO, Julian Baines, has resumed the role in order to stabilise the cost base and accelerate the construction of the fermentation facilities.

Hargreaves Services Plc

Cost £7,912,696 (2,450,000 shares)
Market value £10,216,500 representing 4.95%
of NAV

Hargreaves Services aims to deliver returns in two key asset classes: industrials and the property sector. The business has evolved from a traditional model of industrial services and logistics to incorporate renewable energy, civil engineering, land restoration and remediation. The Company has developed a pipeline of opportunities with a land bank of 18,000 acres across the UK, which will have a mixed-use purpose of residential, commercial property and industrial use.

The company has a stated book value, which we believe to be conservative, of 605p per share, well above the current market price of 384p as of 31 May 2023. In addition, the German joint venture remains a strategic asset to a trade buyer and offers material upside to the current value of the Plc. The land portfolio has had a difficult year as housebuilders pause purchases of new sites, with revenue now likely to be pushed out to the next few years.

Sureserve Group Plc

Cost £3,376,149 (10,000,000 shares)

Market value £8,500,000 representing 4.12% of NAV Sureserve Group provides Compliance and Energy services to customers in the outsourced public and regulated services sectors in the UK. It is the market leader in social housing gas compliance and its markets are driven by government policy.

The company received a bid of 125p per share on the 17th May 2023 which will return circa £12.5 million to the Company, achieving a 268% return on the initial investment.

Tribal Group Plc

Cost £11,603,585 (20,000,000 shares)

Market value £7,840,000 representing 3.80% of NAV Tribal Group is a provider of technology products and services to the education, learning and training markets in the UK and overseas. It is active in administrative functions in three fields: student management services, professional services & analytics, and quality assurance.

The company reported the loss of contract with Singapore based NTU during the year, causing a significant loss of value in the share price. We have increased our stake in the business from 8.5 million shares to 20 million shares in order to capitalize on the decreased valuation. Outside of the loss of the NTU contract the core business has improved year on year, with annual recurring revenue increasing 10% and both the cloud and Edge products marking considerable improvement.

Carr's Group Plc

Cost £5,521,950 (5,000,000 shares)

Market value £6,400,000 representing 3.10% of NAV Carr's Group is an international manufacturer and supplier of market leading brands in the specialty agriculture and engineering sectors. The group divested its Agricultural supplies division in October 2022 in order to focus on its core segments.

The company has appointed Martin Rowland to the board as a representative of Harwood to oversee a strategy to maximise shareholder value.

Investment Schedule as at 31 March 2023

Creat Britain - Equities (87.41%, 2022: 88.13%) Centaur Media Pic 35,000,000.00 16,800,000 8.14 Tribal Group Pic 20,000,000.00 7,840,000 3.80 Hargreaves services Pic 2,455,000.00 10,216,500 4,95 Pendragon Pic 6,000,000.00 2,100,000 0.48 Eckoh Pic 6,000,000.00 852,500 0.41 Redcentric Pic 9,500,000.00 12,635,000 6.12 Niox group Pic 40,000,000.00 14,255,000 6.12 Niox group Pic 40,000,000.00 142,500 0.07 Elfo Diagnostics Holdings Pic 36,000,000.00 17,680,000 8.56 Fulcrum Utility Services Ltd 14,250,000.00 17,250 0.07 Elfo Diagnostics Holdings Pic 2,500,000.00 796,500 0.39 Spire Healthcare Group Pic 2,500,000.00 796,500 0.39 Spire Healthcare Group Pic 2,500,000.00 3,330,000 1.61 Sureserve group Pic 1,000,000.00 3,330,000 1.61 Sureserve group Pic 10,000,000.00 3,330,000 1.61 Sureserve group Pic 10,000,000.00 3,300,000 1.64 Sureserve group Pic 10,000,000.00 3,500,000 1.48 Flowter Fluidipower Pic 2,250,000.00 3,600,000 1.48 Flowter Fluidipower Pic 2,250,000.00 3,000,000 1.48 Flowter Fluidipower Pic 3,001,400,000 3,835,000 1.65 Ninove Pic 3,001,400,000 3,835,000 1.65 Ninove Pic 3,001,477.00 988,221 0.46 Avingtrans Pic 4,000,000.00 3,835,000 1.15 Ninove Pic 3,000,000.00 3,835,000 1.15 Ninove Pic 3,000,000 3,835,		Holding Units	Fair Value £	Proportion of Net Assets %
Centaur Media Plc 35,000,000.00 16,800,000 8.14 Tribal Group Plc 20,000,000.00 7,840,000 3.80 Hargreaves services Plc 2,450,000.00 10,216,500 4.95 Pendragon Plc 6,000,000.00 290,000 0.48 Eckoh Plc 6,000,000.00 2,100,000 1.02 Animalcare Group Plc 550,000.00 852,500 0.41 Redcentric Plc 9,500,000.00 12,635,000 6.12 Niox group Plc 40,000,000.00 17,680,000 8.56 Fulcrum Utility Services Ltd 14,250,000.00 142,500 0.07 Ekfe Diagnostics Holdings Plc 36,000,000.00 796,500 0.39 Esken Ltd 15,000,000.00 796,500 0.39 Spire Healthcare Group Plc 2,500,000.00 5,312,500 2.57 MJ Gleeson Plc 1,000,000.00 4,322,000 2.09 Nahl Group Plc 9,000,000.00 3,333,000 1.61 Sureserve group Plc 10,000,000.00 3,000,000 14,322,750 6.94	LISTED INVESTMENTS			
Tribal Group Ptc 20,000,000.00 7,840,000 3.80 Hargreaves services Ptc 2,450,000.00 10,216,500 4.95 Pendragon Ptc 6,000,000.00 990,000 0.48 Eckoh Ptc 6,000,000.00 2,100,000 1.02 Animalcare Group Ptc 550,000.00 852,500 0.41 Redeentric Ptc 9,500,000.00 12,635,000 6.12 Nix group Ptc 40,000,000.00 17,680,000 8.56 Fulcrum Utility Services Ltd 14,250,000.00 142,500 0.07 Esken Ltd 15,000,000.00 17,680,000 5.39 Esken Ltd 15,000,000.00 76,500 0.39 Spire Healthcare Group Ptc 2,500,000.00 5,312,500 2.57 MG Geson Ptc 1,000,000.00 4,322,000 2.09 Nationary Ptc 9,000,000.00 3,330,000 1.61 Sureserve group Ptc 10,000,000.00 3,500,000 1.43 Curtis Banks Group Ptc 9,000,000.00 3,600,000 1.48 Flowtech Fluidpower Ptc <	Great Britain - Equities (87.41%, 2022: 88.13%)			
Hargreaves services Pic	Centaur Media Plc	35,000,000.00	16,800,000	8.14
Pendragon Plc 6,000,000.00 990,000 0.48 Eckoh Plc 6,000,000.00 2,100,000 1.02 Animalcare Group Plc 550,000.00 852,500 0.41 Redcentric Plc 9,500,000.00 12,635,000 6.12 Nix group Plc 40,000,000.00 17,680,000 8.56 Fulcrum Utility Services Ltd 14,250,000.00 11,124,000 5.39 Ekf Diagnostics Holdings Plc 36,000,000.00 11,124,000 5.39 Esken Ltd 15,000,000.00 796,500 0.39 Spire Healthcare Group Plc 2,500,000.00 5,312,500 2.57 MJ Gleeson Plc 1,000,000.00 4,320,000 2.09 Nahl Group Plc 9,000,000.00 3,330,000 1.61 Sureserve group Plc 10,000,000.00 8,500,000 4.12 Curtis Banks Group Plc 4,225,000.00 14,322,750 6.94 Benchmark Holdings Plc 9,000,000.00 3,600,000 1.18 Flowtech Fluidpower Plc 2,250,000.00 2,295,000 1.11 Smoove	Tribal Group Plc	20,000,000.00	7,840,000	3.80
Eckoh Plc 6,000,000.00 2,100,000 1.02 Animalcare Group Plc 550,000.00 852,500 0.41 Redcentric Plc 9,500,000.00 12,635,000 6.12 Nixo group Plc 40,000,000.00 17,680,000 8.56 Fulcrum Utility Services Ltd 14,250,000.00 142,500 0.07 Ekf Diagnostics Holdings Plc 36,000,000.00 11,124,000 5.39 Esken Ltd 15,000,000.00 796,500 0.39 Spire Healthcare Group Plc 2,500,000.00 5,312,500 2.57 MJ Gleeson Plc 1,000,000.00 4,320,000 2.09 Nahl Group Plc 9,000,000.00 3,330,000 1.61 Sureserve group Plc 10,000,000.00 8,500,000 4.12 Curt's Banks Group Plc 4,225,000.00 14,322,750 6.94 Benchmark Holdings Plc 9,000,000.00 3,060,000 1.48 Flowtech Fluidpower Plc 2,250,000.00 3,060,000 1.13 Smoove Plc 3,041,972.00 958,221 0.46 Avingtrans P	Hargreaves services Plc	2,450,000.00	10,216,500	4.95
Animalcare Group Plc Redcentric Redcentric Plc Redcentric Redcentric Plc Redcentr	Pendragon Plc	6,000,000.00	990,000	0.48
Redcentric Plc 9,500,000.00 12,635,000 6.12 Nix group Plc 40,000,000.00 17,680,000 8.56 Fulcrum Utility Services Ltd 14,250,000.00 142,500 0.07 Ekf Diagnostics Holdings Plc 36,000,000.00 11,124,000 5.39 Esken Ltd 15,000,000.00 796,500 0.39 Spire Healthcare Group Plc 2,500,000.00 5,312,500 2.57 MJ Gleeson Plc 1,000,000.00 4,320,000 2.09 Mahl Group Plc 9,000,000.00 3,330,000 1.61 Sureserve group Plc 10,000,000.00 8,500,000 4.12 Curtis Banks Group Plc 4,225,000.00 14,322,750 6.94 Benchmark Holdings Plc 9,000,000.00 3,060,000 1.48 Flowtech Fluidpower Plc 2,250,000.00 2,295,000 1.11 Smoove Plc 3,041,972.00 958,221 0.46 Avingtrans Plc 4,000,000.00 16,400,000 7.94 Bigblu Broadband Plc 6,500,000.00 3,835,000 1.15 The	Eckoh Plc	6,000,000.00	2,100,000	1.02
Niox group Plc 40,000,000.00 17,680,000 8.56 Fulcrum Utility Services Ltd 14,250,000.00 142,500 0.07 Ekf Diagnostics Holdings Plc 36,000,000.00 11,124,000 5.39 Spire Healthcare Group Plc 2,500,000.00 796,500 0.39 Spire Healthcare Group Plc 1,000,000.00 4,320,000 2.09 Nahl Group Plc 9,000,000.00 3,330,000 1.61 Sureserve group Plc 10,000,000.00 8,500,000 4.12 Curtis Banks Group Plc 4,225,000.00 14,322,750 6.94 Benchmark Holdings Plc 9,000,000.00 3,060,000 1.48 Flowtech Fluidpower Plc 2,250,000.00 2,295,000 1.11 Smoove Plc 3,041,972.00 958,221 0.46 Avingtrans Plc 4,000,000.00 16,400,000 7.94 Bigblu Broadband Plc 6,500,000.0 2,380,000 1.15 The Fulham Shore Plc 5,000,000.0 5,000,000 2,380,000 1.15 The Fulham Shore Plc 7,220,000.0 938,600	Animalcare Group Plc	550,000.00	852,500	0.41
Fulcrum Utility Services Ltd 14,250,000.00 142,500 0.07 Ekf Diagnostics Holdings Plc 36,000,000.00 11,124,000 5.39 Esken Ltd 15,000,000.00 796,500 0.39 Spire Healthcare Group Plc 2,500,000.00 5,312,500 2.57 MJ Gleeson Plc 1,000,000.00 4,320,000 2.09 Nahl Group Plc 9,000,000.00 3,330,000 1.61 Sureserve group Plc 10,000,000.00 8,500,000 4.12 Curtis Banks Group Plc 4,225,000.00 14,322,750 6,94 Benchmark Holdings Plc 9,000,000.00 3,060,000 1.48 Flowtech Fluidpower Plc 2,250,000.00 2,295,000 1.11 Smoove Plc 3,041,972.00 958,221 0.46 Avingtrans Plc 4,000,000.00 16,400,000 7,94 Bigblu Broadband Plc 6,500,000.00 3,835,000 1.86 Renalytix Plc 2,800,000.00 2,380,000 1.15 The Fulham Shore Plc 5,000,000.00 500,000 0.24 We	Redcentric Plc	9,500,000.00	12,635,000	6.12
Ekf Diagnostics Holdings Plc 36,000,000.00 11,124,000 5.39 Esken Ltd 15,000,000.00 796,500 0.39 Spire Healthcare Group Plc 2,500,000.00 5,312,500 2.57 MJ Gleeson Plc 1,000,000.00 4,320,000 2.09 Nahl Group Plc 9,000,000.00 3,330,000 1.61 Sureserve group Plc 10,000,000.00 8,500,000 4.12 Curtis Banks Group Plc 4,225,000.00 14,322,750 6.94 Benchmark Holdings Plc 9,000,000.00 3,060,000 1.48 Elowtech Fluidpower Plc 2,250,000.00 2,295,000 1.11 Smoove Plc 3,041,972.00 958,221 0.46 Avingtrans Plc 4,000,000.00 3,835,000 1.86 Renalytix Plc 2,800,000.00 3,835,000 1.86 Renalytix Plc 2,800,000.00 2,380,000 1.15 The Fulham Shore Plc 5,000,000.00 3,835,000 0.24 Tissue Regenix Group Plc 1,000,000,000.00 3,860,00 0.25 Trellus	Niox group Plc	40,000,000.00	17,680,000	8.56
Esken Ltd 15,000,000.00 796,500 0.39 Spire Healthcare Group Plc 2,500,000.00 5,312,500 2.57 MJ Gleeson Plc 1,000,000.00 4,320,000 2.09 Nahl Group Plc 9,000,000.00 3,330,000 1.61 Sureserve group Plc 10,000,000.00 8,500,000 4.12 Curtis Banks Group Plc 4,225,000.00 14,322,750 6.94 Benchmark Holdings Plc 9,000,000.00 3,060,000 1.48 Flowtech Fluidpower Plc 2,250,000.00 2,295,000 1.11 Smoove Plc 3,041,972.00 958,221 0.46 Avingtrans Plc 4,000,000.00 16,400,000 7.94 Bigblu Broadband Plc 6,500,000.00 3,835,000 1.15 The Fulham Shore Plc 2,800,000.00 2,380,000 1.15 The Fulham Shore Plc 1,000,000,000 500,000 2.71 Verici Dx Plc 7,220,000.00 50,600,000 2.71 Verici Dx Plc 7,220,000.00 388,600 0.25 Trellus Health Plc	Fulcrum Utility Services Ltd	14,250,000.00	142,500	0.07
Spire Healthcare Group Plc 2,500,000.00 5,312,500 2.57 MJ Gleeson Plc 1,000,000.00 4,320,000 2.09 Nahl Group Plc 9,000,000.00 3,330,000 1.61 Sureserve group Plc 10,000,000.00 8,500,000 4.12 Curtis Banks Group Plc 4,225,000.00 14,322,750 6.94 Benchmark Holdings Plc 9,000,000.00 3,060,000 1.48 Flowtech Fluidpower Plc 2,250,000.00 2,295,000 1.11 Smoove Plc 3,041,972.00 958,221 0.46 Avingtrans Plc 4,000,000.00 16,400,000 7.94 Bigblu Broadband Plc 6,500,000.00 3,835,000 1.86 Renalytix Plc 2,800,000.00 2,380,000 1.15 The Fulham Shore Plc 5,000,000.00 500,000 2.71 Verici Dx Plc 7,220,000.00 938,600 0.45 Maintel Holdings Plc 2,350,000.00 380,000 0.15 Kitwave Group Plc 2,250,000.00 300,000 2.92 Induction Healthcare Gr	Ekf Diagnostics Holdings Plc	36,000,000.00	11,124,000	5.39
MJ Gleeson Plc 1,000,000.00 4,320,000 2.09 Nahl Group Plc 9,000,000.00 3,330,000 1.61 Sureserve group Plc 10,000,000.00 8,500,000 4.12 Curtis Banks Group Plc 4,225,000.00 14,322,750 6.94 Benchmark Holdings Plc 9,000,000.00 3,060,000 1.48 Flowtech Fluidpower Plc 2,250,000.00 2,295,000 1.11 Smoove Plc 3,041,972.00 958,221 0.46 Avingtrans Plc 4,000,000.00 16,400,000 7.94 Bigblu Broadband Plc 6,500,000.00 3,835,000 1.86 Renalytix Plc 2,800,000.00 2,380,000 1.15 The Fulham Shore Plc 5,000,000.00 500,000 2.71 Tissue Regenix Group Plc 1,000,000,000.00 5600,000 2.71 Verici Dx Plc 7,220,000.00 938,600 0.45 Maintel Holdings Plc 2,350,000.00 300,000 0.15 Kitwave Group Plc 2,250,000.00 6,030,000 2.92 Induction Healthcare	Esken Ltd	15,000,000.00	796,500	0.39
MJ Gleeson Plc 1,000,000.00 4,320,000 2.09 Nahl Group Plc 9,000,000.00 3,330,000 1.61 Sureserve group Plc 10,000,000.00 8,500,000 4.12 Curtis Banks Group Plc 4,225,000.00 14,322,750 6.94 Benchmark Holdings Plc 9,000,000.00 3,060,000 1.48 Flowtech Fluidpower Plc 2,250,000.00 2,295,000 1.11 Smoove Plc 3,041,972.00 958,221 0.46 Avingtrans Plc 4,000,000.00 16,400,000 7.94 Bigblu Broadband Plc 6,500,000.00 3,835,000 1.86 Renalytix Plc 2,800,000.00 2,380,000 1.15 The Fulham Shore Plc 5,000,000.00 5,000,000 2.71 Verici Dx Plc 1,000,000,000.00 5600,000 2.71 Verici Dx Plc 7,220,000.00 938,600 0.45 Maintel Holdings Plc 2,350,000.00 300,000 0.15 Kitwave Group Plc 2,250,000.00 6,030,000 2.92 Induction Healthcare Group <td>Spire Healthcare Group Plc</td> <td>2,500,000.00</td> <td>5,312,500</td> <td>2.57</td>	Spire Healthcare Group Plc	2,500,000.00	5,312,500	2.57
Nahl Group Plc 9,000,000.00 3,330,000 1.61 Sureserve group Plc 10,000,000.00 8,500,000 4.12 Curtis Banks Group Plc 4,225,000.00 14,322,750 6.94 Benchmark Holdings Plc 9,000,000.00 3,060,000 1.48 Flowtech Fluidpower Plc 2,250,000.00 2,295,000 1.11 Smoove Plc 3,041,972.00 958,221 0.46 Avingtrans Plc 4,000,000.00 16,400,000 7.94 Bigblu Broadband Plc 6,500,000.00 3,835,000 1.15 The Fulham Shore Plc 2,800,000.00 2,380,000 1.15 The Fulham Shore Plc 1,000,000,000.00 500,000 0.24 Maintel Holdings Plc 7,220,000.00 938,600 0.45 Maintel Holdings Plc 2,350,000.00 2,585,000 0.15 Kitwave Group Plc 2,350,000.00 300,000 0.15 Kitwave Group Plc 2,250,000.00 6,030,000 2.92 Induction Healthcare Group 4,500,000.00 900,000 0.44 On	MJ Gleeson Plc	1,000,000.00	4,320,000	2.09
Sureserve group Plc 10,000,000.00 8,500,000 4.12 Curtis Banks Group Plc 4,225,000.00 14,322,750 6.94 Benchmark Holdings Plc 9,000,000.00 3,060,000 1.48 Flowtech Fluidpower Plc 2,250,000.00 2,295,000 1.11 Smoove Plc 3,041,972.00 958,221 0.46 Avingtrans Plc 4,000,000.00 16,400,000 7.94 Bigblu Broadband Plc 6,500,000.00 3,835,000 1.86 Renalytix Plc 2,800,000.00 2,380,000 1.15 The Fulham Shore Plc 5,000,000.00 500,000 0.24 Tissue Regenix Group Plc 1,000,000,000.00 5,600,000 2.71 Verici Dx Plc 7,220,000.00 938,600 0.45 Maintel Holdings Plc 2,350,000.00 2,585,000 0.25 Trellus Health Plc 5,000,000.00 300,000 0.15 Kitwave Group Plc 2,250,000.00 6,030,000 2.92 Induction Healthcare Group 4,500,000.00 900,000 0.44 Other	Nahl Group Plc			1.61
Curtis Banks Group Plc 4,225,000.00 14,322,750 6.94 Benchmark Holdings Plc 9,000,000.00 3,060,000 1.48 Flowtech Fluidpower Plc 2,250,000.00 2,295,000 1.11 Smoove Plc 3,041,972.00 958,221 0.46 Avingtrans Plc 4,000,000.00 16,400,000 7.94 Bigblu Broadband Plc 6,500,000.00 3,835,000 1.86 Renalytix Plc 2,800,000.00 2,380,000 1.15 The Fulham Shore Plc 5,000,000.00 500,000 0.24 Tissue Regenix Group Plc 1,000,000,000.00 5,600,000 2.71 Verici Dx Plc 7,220,000.00 938,600 0.45 Maintel Holdings Plc 2,350,000.00 2,585,000 1.25 Trellus Health Plc 5,000,000.00 300,000 0.15 Kitwave Group Plc 2,250,000.00 6,030,000 2.92 Induction Healthcare Group 4,500,000.00 900,000 0.44 Onthemarket Plc 3,000,000.00 280,220 0.14 Facilities b	Sureserve group Plc			4.12
Benchmark Holdings Plc 9,000,000.00 3,060,000 1.48 Flowtech Fluidpower Plc 2,250,000.00 2,295,000 1.11 Smoove Plc 3,041,972.00 958,221 0.46 Avingtrans Plc 4,000,000.00 16,400,000 7.94 Bigblu Broadband Plc 6,500,000.00 3,835,000 1.86 Renalytix Plc 2,800,000.00 2,380,000 1.15 The Fulham Shore Plc 5,000,000.00 500,000 0.24 Tissue Regenix Group Plc 1,000,000,000.00 5,600,000 2.71 Verici Dx Plc 7,220,000.00 938,600 0.45 Maintel Holdings Plc 2,350,000.00 2,585,000 1.25 Trellus Health Plc 5,000,000.00 300,000 2.92 Induction Healthcare Group 4,500,000.00 900,000 0.44 Onthemarket Plc 3,078,913.00 2,062,872 1.00 Carr's Group Plc 5,000,000.00 6,400,000 3.10 4global Plc 5,49,450.00 280,220 0.14 Facilities by Adf Plc	Curtis Banks Group Plc		14,322,750	6.94
Flowtech Fluidpower Plc 2,250,000.00 2,295,000 1.11 Smoove Plc 3,041,972.00 958,221 0.46 Avingtrans Plc 4,000,000.00 16,400,000 7.94 Bigblu Broadband Plc 6,500,000.00 3,835,000 1.86 Renalytix Plc 2,800,000.00 2,380,000 1.15 The Fulham Shore Plc 5,000,000.00 500,000 0.24 Tissue Regenix Group Plc 1,000,000,000.00 5,600,000 2.71 Verici Dx Plc 7,220,000.00 938,600 0.45 Maintel Holdings Plc 2,350,000.00 2,585,000 1.25 Trellus Health Plc 5,000,000.00 300,000 0.15 Kitwave Group Plc 2,250,000.00 6,030,000 2.92 Induction Healthcare Group 4,500,000.00 900,000 0.44 Onthemarket Plc 3,078,913.00 2,062,872 1.00 Carr's Group Plc 5,000,000.00 6,400,000 3.10 4global Plc 549,450.00 280,220 0.14 Facilities by Adf Plc	Benchmark Holdings Plc			1.48
Smoove Plc 3,041,972.00 958,221 0.46 Avingtrans Plc 4,000,000.00 16,400,000 7.94 Bigblu Broadband Plc 6,500,000.00 3,835,000 1.86 Renalytix Plc 2,800,000.00 2,380,000 1.15 The Fulham Shore Plc 5,000,000.00 500,000 0.24 Tissue Regenix Group Plc 1,000,000,000.00 5,600,000 2.71 Verici Dx Plc 7,220,000.00 938,600 0.45 Maintel Holdings Plc 2,350,000.00 2,585,000 1.25 Trellus Health Plc 5,000,000.00 300,000 0.15 Kitwave Group Plc 2,250,000.00 6,030,000 2.92 Induction Healthcare Group 4,500,000.00 900,000 0.44 Onthemarket Plc 3,078,913.00 2,062,872 1.00 Carr's Group Plc 5,000,000.00 6,400,000 3.10 4global Plc 549,450.00 280,220 0.14 Facilities by Adf Plc 1,500,000.00 937,500 0.45 React Group Plc 3,0			2,295,000	1.11
Avingtrans Plc 4,000,000.00 16,400,000 7.94 Bigblu Broadband Plc 6,500,000.00 3,835,000 1.86 Renalytix Plc 2,800,000.00 2,380,000 1.15 The Fulham Shore Plc 5,000,000.00 500,000 0.24 Tissue Regenix Group Plc 1,000,000,000.00 5,600,000 2.71 Verici Dx Plc 7,220,000.00 938,600 0.45 Maintel Holdings Plc 2,350,000.00 2,585,000 1.25 Trellus Health Plc 5,000,000.00 300,000 0.15 Kitwave Group Plc 2,250,000.00 6,030,000 2.92 Induction Healthcare Group 4,500,000.00 900,000 0.44 Onthemarket Plc 3,078,913.00 2,062,872 1.00 Carr's Group Plc 5,000,000.00 6,400,000 3.10 4global Plc 549,450.00 280,220 0.14 Facilities by Adf Plc 1,500,000.00 937,500 0.45 React Group Plc 30,000,000.00 300,000 0.15 Assetco Plc 3,000,000.00 1,7110,000 0.83 Catalyst Media Group P				0.46
Bigblu Broadband Plc 6,500,000.00 3,835,000 1.86 Renalytix Plc 2,800,000.00 2,380,000 1.15 The Fulham Shore Plc 5,000,000.00 500,000 0.24 Tissue Regenix Group Plc 1,000,000,000.00 5,600,000 2.71 Verici Dx Plc 7,220,000.00 938,600 0.45 Maintel Holdings Plc 2,350,000.00 2,585,000 1.25 Trellus Health Plc 5,000,000.00 300,000 0.15 Kitwave Group Plc 2,250,000.00 6,030,000 2.92 Induction Healthcare Group 4,500,000.00 900,000 0.44 Onthemarket Plc 3,078,913.00 2,062,872 1.00 Carr's Group Plc 5,000,000.00 6,400,000 3.10 4global Plc 549,450.00 280,220 0.14 Facilities by Adf Plc 1,500,000.00 937,500 0.45 React Group Plc 30,000,000.00 300,000 0.15 Assetco Plc 3,000,000.00 5,152,500 2.50 Catalyst Media Group Plc	Avingtrans Plc			7.94
Renalytix Plc 2,800,000.00 2,380,000 1.15 The Fulham Shore Plc 5,000,000.00 500,000 0.24 Tissue Regenix Group Plc 1,000,000,000.00 5,600,000 2.71 Verici Dx Plc 7,220,000.00 938,600 0.45 Maintel Holdings Plc 2,350,000.00 2,585,000 1.25 Trellus Health Plc 5,000,000.00 300,000 0.15 Kitwave Group Plc 2,250,000.00 6,030,000 2.92 Induction Healthcare Group 4,500,000.00 900,000 0.44 Onthemarket Plc 3,078,913.00 2,062,872 1.00 Carr's Group Plc 5,000,000.00 6,400,000 3.10 4global Plc 549,450.00 280,220 0.14 Facilities by Adf Plc 1,500,000.00 870,000 0.42 Hostmore Plc 7,500,000.00 300,000 0.15 React Group Plc 30,000,000.00 300,000 0.15 Assetco Plc 3,000,000.00 5,152,500 2.50 Catalyst Media Group Plc 3,435,000.00 5,152,500 2.50			3,835,000	1.86
The Fulham Shore Plc 5,000,000.00 500,000 0.24 Tissue Regenix Group Plc 1,000,000,000.00 5,600,000 2.71 Verici Dx Plc 7,220,000.00 938,600 0.45 Maintel Holdings Plc 2,350,000.00 2,585,000 1.25 Trellus Health Plc 5,000,000.00 300,000 0.15 Kitwave Group Plc 2,250,000.00 6,030,000 2.92 Induction Healthcare Group 4,500,000.00 900,000 0.44 Onthemarket Plc 3,078,913.00 2,062,872 1.00 Carr's Group Plc 5,000,000.00 6,400,000 3.10 4global Plc 549,450.00 280,220 0.14 Facilities by Adf Plc 1,500,000.00 870,000 0.42 Hostmore Plc 7,500,000.00 937,500 0.45 React Group Plc 30,000,000.00 300,000 0.15 Assetco Plc 3,000,000.00 5,152,500 2.50				1.15
Tissue Regenix Group Plc 1,000,000,000.00 5,600,000 2.71 Verici Dx Plc 7,220,000.00 938,600 0.45 Maintel Holdings Plc 2,350,000.00 2,585,000 1.25 Trellus Health Plc 5,000,000.00 300,000 0.15 Kitwave Group Plc 2,250,000.00 6,030,000 2.92 Induction Healthcare Group 4,500,000.00 900,000 0.44 Onthemarket Plc 3,078,913.00 2,062,872 1.00 Carr's Group Plc 5,000,000.00 6,400,000 3.10 4global Plc 549,450.00 280,220 0.14 Facilities by Adf Plc 1,500,000.00 870,000 0.42 Hostmore Plc 7,500,000.00 937,500 0.45 React Group Plc 30,000,000.00 300,000 0.15 Assetco Plc 3,000,000.00 1,710,000 0.83 Catalyst Media Group Plc 3,435,000.00 5,152,500 2.50	The Fulham Shore Plc			0.24
Verici Dx Plc 7,220,000.00 938,600 0.45 Maintel Holdings Plc 2,350,000.00 2,585,000 1.25 Trellus Health Plc 5,000,000.00 300,000 0.15 Kitwave Group Plc 2,250,000.00 6,030,000 2.92 Induction Healthcare Group 4,500,000.00 900,000 0.44 Onthemarket Plc 3,078,913.00 2,062,872 1.00 Carr's Group Plc 5,000,000.00 6,400,000 3.10 4global Plc 549,450.00 280,220 0.14 Facilities by Adf Plc 1,500,000.00 870,000 0.42 Hostmore Plc 7,500,000.00 937,500 0.45 React Group Plc 30,000,000.00 300,000 0.15 Assetco Plc 3,000,000.00 1,710,000 0.83 Catalyst Media Group Plc 3,435,000.00 5,152,500 2.50			· ·	
Maintel Holdings Plc 2,350,000.00 2,585,000 1.25 Trellus Health Plc 5,000,000.00 300,000 0.15 Kitwave Group Plc 2,250,000.00 6,030,000 2.92 Induction Healthcare Group 4,500,000.00 900,000 0.44 Onthemarket Plc 3,078,913.00 2,062,872 1.00 Carr's Group Plc 5,000,000.00 6,400,000 3.10 4global Plc 549,450.00 280,220 0.14 Facilities by Adf Plc 1,500,000.00 870,000 0.42 Hostmore Plc 7,500,000.00 937,500 0.45 React Group Plc 30,000,000.00 300,000 0.15 Assetco Plc 3,000,000.00 1,710,000 0.83 Catalyst Media Group Plc 3,435,000.00 5,152,500 2.50				
Trellus Health Plc 5,000,000.00 300,000 0.15 Kitwave Group Plc 2,250,000.00 6,030,000 2.92 Induction Healthcare Group 4,500,000.00 900,000 0.44 Onthemarket Plc 3,078,913.00 2,062,872 1.00 Carr's Group Plc 5,000,000.00 6,400,000 3.10 4global Plc 549,450.00 280,220 0.14 Facilities by Adf Plc 1,500,000.00 870,000 0.42 Hostmore Plc 7,500,000.00 937,500 0.45 React Group Plc 30,000,000.00 300,000 0.15 Assetco Plc 3,000,000.00 1,710,000 0.83 Catalyst Media Group Plc 3,435,000.00 5,152,500 2.50	Maintel Holdings Plc		· ·	1.25
Kitwave Group Plc 2,250,000.00 6,030,000 2.92 Induction Healthcare Group 4,500,000.00 900,000 0.44 Onthemarket Plc 3,078,913.00 2,062,872 1.00 Carr's Group Plc 5,000,000.00 6,400,000 3.10 4global Plc 549,450.00 280,220 0.14 Facilities by Adf Plc 1,500,000.00 870,000 0.42 Hostmore Plc 7,500,000.00 937,500 0.45 React Group Plc 30,000,000.00 300,000 0.15 Assetco Plc 3,000,000.00 1,710,000 0.83 Catalyst Media Group Plc 3,435,000.00 5,152,500 2.50	5			
Induction Healthcare Group 4,500,000.00 900,000 0.44 Onthemarket Plc 3,078,913.00 2,062,872 1.00 Carr's Group Plc 5,000,000.00 6,400,000 3.10 4global Plc 549,450.00 280,220 0.14 Facilities by Adf Plc 1,500,000.00 870,000 0.42 Hostmore Plc 7,500,000.00 937,500 0.45 React Group Plc 30,000,000.00 300,000 0.15 Assetco Plc 3,000,000.00 1,710,000 0.83 Catalyst Media Group Plc 3,435,000.00 5,152,500 2.50			· ·	
Onthemarket Plc 3,078,913.00 2,062,872 1.00 Carr's Group Plc 5,000,000.00 6,400,000 3.10 4global Plc 549,450.00 280,220 0.14 Facilities by Adf Plc 1,500,000.00 870,000 0.42 Hostmore Plc 7,500,000.00 937,500 0.45 React Group Plc 30,000,000.00 300,000 0.15 Assetco Plc 3,000,000.00 1,710,000 0.83 Catalyst Media Group Plc 3,435,000.00 5,152,500 2.50				
Carr's Group Plc 5,000,000.00 6,400,000 3.10 4global Plc 549,450.00 280,220 0.14 Facilities by Adf Plc 1,500,000.00 870,000 0.42 Hostmore Plc 7,500,000.00 937,500 0.45 React Group Plc 30,000,000.00 300,000 0.15 Assetco Plc 3,000,000.00 1,710,000 0.83 Catalyst Media Group Plc 3,435,000.00 5,152,500 2.50	·		· ·	
4global Plc 549,450.00 280,220 0.14 Facilities by Adf Plc 1,500,000.00 870,000 0.42 Hostmore Plc 7,500,000.00 937,500 0.45 React Group Plc 30,000,000.00 300,000 0.15 Assetco Plc 3,000,000.00 1,710,000 0.83 Catalyst Media Group Plc 3,435,000.00 5,152,500 2.50				
Facilities by Adf Plc 1,500,000.00 870,000 0.42 Hostmore Plc 7,500,000.00 937,500 0.45 React Group Plc 30,000,000.00 300,000 0.15 Assetco Plc 3,000,000.00 1,710,000 0.83 Catalyst Media Group Plc 3,435,000.00 5,152,500 2.50				
Hostmore Plc 7,500,000.00 937,500 0.45 React Group Plc 30,000,000.00 300,000 0.15 Assetco Plc 3,000,000.00 1,710,000 0.83 Catalyst Media Group Plc 3,435,000.00 5,152,500 2.50				
React Group Plc 30,000,000.00 300,000 0.15 Assetco Plc 3,000,000.00 1,710,000 0.83 Catalyst Media Group Plc 3,435,000.00 5,152,500 2.50				
Assetco Plc 3,000,000.00 1,710,000 0.83 Catalyst Media Group Plc 3,435,000.00 5,152,500 2.50				
Catalyst Media Group Plc 3,435,000.00 5,152,500 2.50				
		-, .30,000.00		

Investment Schedule (continued)

	Holding Units	Fair Value £	Proportion of Net Assets %
LISTED INVESTMENTS (continued)			
Bermuda Islands - Equities (1.05%, 2022: 1.29%)			
Randall + Quilter Investment Holdings Ltd	3,000,000	2,172,000	1.05
		2,172,000	1.05
USA - Equities (0.31%, 2022: 0.23%)			
Spectra Systems Corp	350,000	630,000	0.31
		630,000	0.31
Total listed investments		183,259,163	88.77
UNLISTED INVESTMENTS			
Great Britain - Equities (1.94%, 2022: 2.89%)			
IPT Group Limited	112,498	-	-
Moxico Resources Plc	3,000,000	1,500,000	0.73
Prefcap Ltd	305,210	-	-
Sinav Limited	437,033	176,732	0.09
Studio Retail Group Plc	250,000	-	-
Tradewise Group of Companies Limited	1,094,528	-	-
Urban Exposure Plc	2,700,000	27,000	0.01
Sourcebioscience International Plc	2,000,000	2,300,000	1.11
		4,003,732	1.94
Great Britain - Limited Partnership Interest (0.00%, 2022:	0.00%)		
BDB1 LLP (Rileys/Indicant)	1,258	-	-
		-	-
Spain - Equities (1.57%, 2022: 1.30%)			
GYG Plc	10,485,947	3,250,644	1.57
		3,250,644	1.57
USA - Equities (0.51%, 2022: 0.41%)			
Jaguar Holdings Limited	665,761	1,049,986	0.51
		1,049,986	0.51
USA - Debt (0.59%, 2022: 0.66%)			
Jaguar Holdings Limited	532,309	1,226,986	0.59
		1,226,986	0.59

Investment Schedule (continued)

	Holding Units	Fair Value £	Proportion of Net Assets %
UNLISTED INVESTMENTS (continued)			
Cayman Islands - Debt (0.12%, 2022: n/a)			
Fulcrum Utilities	250,000	250,000	0.12
		250,000	0.12
Total unlisted investments		9,781,348	4.74
Total investments		193,040,511	93.51
Cash		15,591,410	7.55
Net current liabilities		(2,199,043)	(1.06)
Total net assets		206,432,878	100.00

Refer to note 15 for further information on Segment Information.

Principal Activities

The principal activity of the Company is to carry out business as an investment Company. The Directors do not envisage any changes in this activity for the foreseeable future.

Structure

The Company is a Guernsey Authorised Closed-Ended Collective Investment Scheme pursuant to the Protection of Investors (Bailiwick of Guernsey) Law 2020, as amended, and the Authorised Closed Ended Investment Scheme Rules 2022 issued by the Guernsey Financial Services Commission ("GFSC"). It was incorporated and registered with limited liability in Guernsey on 2 December 1994, with registration number 28917. The Company has a premium listing on the Main Market of the London Stock Exchange.

Purpose

The purpose of the Company is to generate abovemarket returns, as measured against the appropriate index, over the medium and long term through investment in small and medium size companies.

Investment Policy

The Company principally invests in small and mid-size quoted and unquoted companies in the UK and US. The Investment Manager targets companies that have fundamentally strong business models but where there may be specific factors which are constraining the maximisation or realisation of shareholder value, which may be realised through the pursuit of an activist shareholder agenda by the Investment Manager. Dividend income is a secondary consideration when making investment decisions.

Achieving the Investment Policy

The investment approach of the Investment Manager is characterised by a rigorous focus on research and

financial analysis of potential investee companies so that a thorough understanding of their business models is gained prior to investment. Comprehensive due diligence, including one or more meetings with management, as well as site visits, are standard procedures before shares are acquired.

Typically the portfolio will comprise of 40 to 60 holdings (but without restricting the Company from holding a more or less concentrated portfolio in the future).

The Company may invest in derivatives, financial instruments, money market instruments and currencies solely for the purpose of efficient portfolio management (i.e. solely for the purpose of reducing, transferring or eliminating investment risk in the Company's investments, including any technique or instrument used to provide protection against exchange and credit risks).

The Investment Manager expects that the Company's assets will normally be fully invested. During periods in which changes in economic conditions or other factors so warrant, the Company may reduce its exposure to securities and increase its position in cash and money market instruments.

A detailed description of the key risk controls employed by the Investment Manager is disclosed in note 16 of the financial statements. An analysis of the Company's portfolio is disclosed on pages 5 to 10 including a description of the ten largest equity investments. At the year end, the Company's portfolio consisted of 55 holdings (2022: 58 holdings). The top 10 holdings represented 59.06% (2022: 55.81%) of net assets.

The Board is responsible for determining the gearing strategy for the Company. Gearing is used selectively to leverage the Company's portfolio in order to enhance returns where, and to the extent this is considered appropriate, to do so. Borrowings are short term and particular care is taken to ensure that any bank covenants permit maximum flexibility of the investment policy. The Company does not currently have any borrowings.

The Company may only make material changes to its investment policy with the approval of shareholders (in the form of an ordinary resolution).

Investment Restrictions

The Company has adopted the following policies:

- (a) it will not invest in securities carrying unlimited liability;
- (b) short selling for the purpose of efficient portfolio management will be permitted provided that the aggregate value of the securities subject to a contract for sale that has not been settled and which are not owned by the Company shall not exceed 20 percent of the NAV. In addition, the Company may engage in uncollateralised stock lending on normal commercial terms with counterparties whose ordinary business includes uncollateralised stock lending provided that the aggregate exposure of the Company to any single counterparty shall not exceed 20 percent of the NAV;
- (c) it will not take legal or management control of investments in its portfolio;
- (d) it will not buy or sell commodities or commodity contracts or real estate or interests in real estate

- although it may purchase and sell securities which are secured by real estate or commodities and securities of companies which invest in or deal in real estate commodities;
- (e) it will not invest or lend more than 20 percent of its assets in securities of any one Company or single issuer;
- it will not invest more than 35 percent of its assets in securities not listed or quoted on any recognised stock exchange;
- (g) it will not invest in any Company where the investment would result in the Company holding more than 10 percent of the issued share capital of that Company or any class of that share capital, unless that Company constitutes a trading Company (for the purposes of the relevant UK legislation) in which case the Company may not make any investment that would result in it holding 50 percent or more of the issued share capital of that Company or of any class of that share capital;
- (h) it will not invest more than 5 percent of its assets in units of unit trusts or shares or other forms of participation in managed open-ended investment vehicles;
- (i) the Company may use options, foreign exchange transactions on the forward market, futures and contracts for differences for the purpose of efficient portfolio management provided that:
 - (1) in the case of options, this is done on a covered basis:

- (2) in the case of futures and forward foreign exchange transactions, the face value of all such contracts does not exceed 100 percent of the NAV of the Company; or
- (3) in the case of contracts for difference (including stock index future or options) the face value of all such contracts does not exceed 100 percent of NAV of the Company.

None of these restrictions, however, require the realisation of any assets of the Company where any restriction is breached as a result of an event outside the control of the Investment Manager which occurs after the investment is made, but no further relevant assets may be acquired by the Company until the relevant restriction can again be complied with. In the event of any breach of these investment restrictions, the Board will as soon as practicable make an announcement on a Regulatory Information Service and subsequently write to shareholders if appropriate; and

(j) the Company will ensure gearing does not exceed 20% of net assets.

Principal Risks and Uncertainties

The Directors confirm that they have carried out a robust assessment of the principal and emerging risks facing the Company, including those that would threaten its business model, future performance, solvency, or liquidity.

The Board is responsible for the Company's system of internal controls and for reviewing its effectiveness. The Board also monitors the investment limits and restrictions set out in the Company's investment objective and policy.

The principal and emerging risks that have been identified and the steps taken by the Board to mitigate these are as follows:

Principal risk

Investment activity and performance

An inappropriate investment strategy may result in under performance against the Company's objectives. The Board manages these risks by ensuring a diversification of investments.

Mitigating factor

The Investment Manager operates in accordance with the investment limits and restrictions policy determined by the Board. The Directors review the limits and restrictions on a regular basis and BNP Paribas S.A., Guernsey Branch (the "Administrator") monitors adherence to the limits and restrictions every month and notifies the Board of any breach. The Investment Manager provides the Board with management information including performance data and reports, and the Stockbroker provides shareholder analysis. The Directors monitor the implementation and results of the investment process with the Investment Manager at each Board meeting and monitor risk factors in respect of the portfolio. Investment strategy is reviewed regularly.

Principal risk Mitigating factor Level of discount or premium A discount or premium to NAV can occur for a variety While the Directors may seek to mitigate any discount to NAV per Share through share buybacks, of reasons, including market conditions or to the there can be no guarantee that they will do so and extent investors undervalue the management the Directors accept no responsibility for any failure activities of the Investment Manager or discount of any such strategy to effect a reduction in any their valuation methodology and judgement. discount or premium. Market price risk The fair value or future cash flows of a financial The Directors review and agree policies for managing

The fair value or future cash flows of a financial instrument held by the Company may fluctuate because of changes in market prices. This market risk comprises currency risk, interest rate risk and other price risk.

The Directors review and agree policies for managing these risks. The policies have remained substantially unchanged during the year under review. The Investment Manager assesses the exposure to market risk when making each investment decision and monitors the overall level of market price risk on the investment portfolio on an ongoing basis.

Principal risk

Geopolitical factors

Impact of the Russian invasion of Ukraine

The ongoing Ukraine/Russia war continues to have the potential to destabilise global and regional geopolitics, the full effects of which cannot be fully ascertained at this time.

In addition, the ongoing approach by western governments towards the Russian state continues to contribute to significant market dislocations in the supply and cost of petrochemicals. This impact has exacerbated increases in the rate of wholesale price appreciation in the Company's chosen markets, which are having significant impacts on the level of global interest rates and economic activity.

Mitigating factor

The Russian invasion of Ukraine has resulted in high inflationary pressures that has forced the hand of the central bankers to combat by raising interest rates. This has had a negative effect of stock markets.

The Directors take comfort in the fact that the Company's long held strategy of having no, or minor, borrowings and its no-dividend policy will help it withstand short term cash-flow pressures and not require it to sell any material part of its investments under these uncertain conditions. Moreover, as stated in the Investment Manager's Report, the Company's cautious investment approach, targeting healthy and growing businesses with solid financial credentials and cash flows, combined with the close relationship with management teams should minimize the impact of adverse market conditions. It is hoped that this could even provide fruitful opportunities to buy additional shares at significant discounts to fair value in the future. The Board will continue to monitor the effects of the war for direct or indirect impacts on the Company and its future prospects and will report any material change to its assessment as appropriate.

Details of how the Board monitors the services provided by the Investment Manager and the Administrator, and the key elements designed to provide effective internal control are explained further in the internal controls section of the Corporate Governance Statement, which is set out on page 23.

Management, Administration and Custody Arrangements

Harwood Capital Management (Gibraltar) Limited (the "Investment Manager") is an authorised manager by the Gibraltar Financial Services Commission as a small scheme manager to manage Alternative Investment Funds under the Alternative Investment Managers Regulations 2013.

Refer to note 4 for further details on the remuneration of the Investment Manager.

Administration, Custodian and Company Secretarial Services are provided to the Company by BNP Paribas S.A., Guernsey Branch. Registrar services are provided by Link Market Services (Guernsey) Limited.

Related Parties

The Investment Manager and Directors are considered related parties. Please refer to note 18 of the financial statements for further details.

Financial Review

At 31 March 2023, the net assets of the Company were £206,432,878 (2022: £219,409,022). The NAV per Ordinary Share was £14.75 (2022: £15.67). Details on the NAV and basic and diluted loss per Ordinary Share are under note 14 of the financial statements.

Dividend Policy

To the extent that any dividends are paid, they will be paid in accordance with any applicable laws and regulations of the UK Listing Rules and the requirements of the Companies (Guernsey) Law, 2008 (as amended). The Directors do not propose payment of a dividend for the year ended 31 March 2023 (2022: Nil).

Performance Measurement and Key Performance Indicators

In order to measure the success of the Company in meeting its objectives and to evaluate the performance of the Investment Manager, the Directors take into account the following performance indicators:

 Returns and NAV- The Board reviews at each meeting the performance of the portfolio as well as the NAV and share price of the Company.

For and on behalf of the Board

Nigel Cayzer Chairman 5 July 2023

Directors' Report

The Directors present their report and the financial statements of the Company for the year ended 31 March 2023.

Share Capital

The Company's issued share capital as at 31 March 2023 consisted of 14,000,000 (2022: 14,000,000) Ordinary Shares of 50p nominal value each. All shares hold equal rights with no restrictions and no shares carry special rights with regard to the control of the Company.

During the year ended 31 March 2023 and up to the date of approval of these financial statements, the Company has not issued any additional Ordinary Shares.

Buybacks

At the Annual General Meeting ("AGM") of the Company held in August 2022, the Directors were granted the general authority to purchase in the market up to 10% of the Ordinary Shares of each class in issue (as at 18 August 2022). This authority will expire at the forthcoming AGM. The Directors intend to seek annual renewal of this authority from the shareholders.

Pursuant to this authority, and subject to the Companies (Guernsey) Law, 2008 and the discretion of the Directors, the Company may purchase Ordinary Shares of a particular class in the market on an ongoing basis with a view to addressing any imbalance between the supply of and demand for Ordinary Shares of such class, thereby increasing the NAV per Ordinary Share of that class and assisting in controlling the discount to NAV per Ordinary Share of that class in relation to the price at which the Ordinary Shares of such class may be trading.

During the year ended 31 March 2023, no shares were repurchased (2022: 25,000).

Refer to notes 11 and 12 for more information.

Notifications of Shareholdings

As at 31 March 2023, the Company had been notified, in accordance with Chapter 5 of the Disclosure Guidance and Transparency Rules (which covers the acquisition and disposal of major shareholdings and voting rights), of the following shareholders that had an interest of greater than 5% in the Company's issued share capital.

	Number of Shares	Percentage of total voting rights (%)
Harwood Capital LLP ¹	7,375,000	52.68%
Harbor Advisors	1,038,738	7.42%

¹ Harwood Capital LLP as investment manager of North Atlantic Smaller Companies Investment Trust plc ("NASCIT") made the notification of shareholding. However the 7,375,000 shares are held by NASCIT.

Between 1 April 2023 and the date of approval of the financial statements, no additional notifications were received.

Life of the Company

The Company does not have a fixed life. However, under Article 51 of the Articles of Incorporation, the Directors shall give due notice of and propose or cause to be proposed a special resolution that the Company be wound up at the AGM of the Company every two years from 2011 onwards. Notices were tabled at the 2011, 2013, 2015, 2017, 2019 and 2021 AGMs, and in each case were not carried. This was in line with the Board's recommendation to shareholders

to vote against these resolutions. The next notice will be given in the 2023 AGM documents, where the Board expects to recommend that shareholders vote against this resolution.

Going Concern

The Directors have considered the Company's investment objective and risk management policy, its assets and the expected income and return from its investments while factoring in the current economic conditions caused by the Russian invasion of Ukraine, inflation, rising rates and supply chain disruptions. The Directors are of the opinion that the Company is able to meet its liabilities and ongoing expenses as they fall due and they have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. The Directors have a reasonable expectation that the special resolution outlined in Article 51 of the Articles of Incorporation and under "Life of the Company" will not be passed at the AGM scheduled for August 2023. Accordingly, these financial statements have been prepared on a going concern basis and the Directors believe it is appropriate to continue to adopt this basis for a period of at least 12 months from the date of approval of these financial statements.

Viability Statement

At least once a year the Directors are required to carry out a robust assessment of the principal and emerging risks and make a statement which explains how they have assessed the prospects of the Company, over what period they have done so and why they consider that period to be appropriate, taking into account the Company's current position and principal risks. The principal risks faced by the Company are described on pages 13 to 15.

The prospects of the Company are driven by its investment strategy, objectives and policy as summarised on pages 11 to 13, and also by the conditions in the markets in which the Company invests and the financial market in general.

In assessing the prospects of the Company, the Directors have, in addition to taking into account the principal and emerging risks facing the Company, taken into account the Company's current position, which has included a process encompassing an examination of:

- (i) the Investment Manager's view of the market conditions, including the potential impact of the war in Ukraine and investment opportunities in the market to which the Company is exposed, taking into consideration the financial markets generally;
- (ii) the liquidity and prospects of the underlying positions of the Company;
- (iii) the extent to which the Company directly or indirectly uses gearing; and
- (iv) the liquidity of the companies in which the Company invests.

Based on the results of their assessment process, the Directors have concluded that a period of three years from the Statement of Financial Position date is an appropriate period over which to assess the prospects of the Company. Three years is deemed an appropriate time period given the expected holding period needed to realize the Company's investment thesis from individual investments, the general economic outlook, and the time needed for realization of contingencies or claims. Consideration

was also given to the absence of bank borrowings as well as the Company being a closed-ended investment Company. Based on this, combined with the level of cash held and listed investment holdings, the Directors have a reasonable expectation that the Company will be able to continue in operation and meet its liabilities as they fall due within this period of assessment. This three year time period assumes that the special resolution outlined in Article 51 of the Articles of Incorporation, and under "Life of the Company" is not passed at the AGM scheduled for August 2023.

Section 172(1) Statement

Although the Company is domiciled in Guernsey, the Board adheres to the UK Corporate Governance Code and acknowledges its duty to comply with section 172(1) of the UK Companies Act 2006 to act in a way that promotes the success of the Company for the

benefit of its members as a whole, particularly having regard to the shareholders, the service providers and the wider community and environment, as detailed below:

- a) the likely consequences of any long-term decisions;
- b) the need to foster business relationships with suppliers, customers and other parties;
- c) the impact on the wider community and environment;
- d) the desirability of the Company maintaining a high standard of business conduct; and
- e) the need to act fairly between members of the Company.

Who	Why we engage	How we engage	Outcome
Shareholders	Shareholders provide the	The Company engages	Shareholders receive
	necessary capital for the	with Shareholders by:	relevant information
	Company to pursue its purpose and strategy.	 Publishing monthly NAV RNS announcements 	allowing them to make informed decisions about their investments.
		 Publishing the Half Yearly Report and Annual Report 	
		Through interaction at the AGM	

Who	Why we engage	How we engage	Outcome
Service providers	As an investment	The Board receives	The Board receives
	Company with no	formal reports from its	appropriate and timely
	employees, the Company	key service providers	advice and guidance. The
	is reliant on its service	(the Investment Manager,	Board's engagement with
	providers to conduct its	Administrator, Broker and	its service providers
	business.	Registrar) at its quarterly	enables it to help
		Board meetings. There is	facilitate the effective
		frequent informal	running of the Company.
		interaction with the	
		Investment Manager	
		outside of Board	
		meetings.	
The wider community	The Company recognises	In making investment	With every successful
and environment	the benefits to the	decisions, the Company,	investment comes profit
	greater good that will	through its Investment	to the shareholders,
	come from all companies	Manager, identifies small	greater employment for
	being good social	and medium sized	the community at large,
	citizens.	business enterprises that	and growth in the
		have the potential to	innovative small and
		grow their business but	medium business sector
		lack the necessary	of the economy. Such
		funding or management	innovations have
		expertise.	included advanced and
			new products in the key
			healthcare and medical
			equipment industries.

Reappointment of Auditor

RSM CI (Audit) Limited has expressed its willingness to continue in office as auditor and a resolution to reappoint it will be proposed at the Company's forthcoming AGM.

Disclosure of Information to Auditors

The Directors who were members of the Board at the time of approving this Report are listed on pages 24 and 25.

Each of those Directors confirms that:

- to the best of his knowledge and belief, there is no information relevant to the preparation of their report of which RSM CI (Audit) Limited (the "Auditor") is unaware; and
- he has taken all steps a Director might reasonably be expected to have taken to be aware of relevant audit information and to establish that the Company's Auditor is aware of that information.

Dividend

The directors do not recommend the payment of a dividend for the year (2022: £nil).

Financial Instruments

The financial instruments employed by the Company primarily comprise equity and loan stock investments, although it does hold cash and liquid instruments. Further details of the Company's risk management objectives and policies relating to the use of financial instruments can be found in note 16 of the financial statements.

Global Greenhouse Gas Emissions

The Company has no greenhouse gas emissions to report from its operations for the year to 31 March 2023 (2022: none), nor does it have responsibility for any other emissions producing sources.

For and on behalf of the Board

Nigel Cayzer Chairman 5 July 2023

Corporate Governance Report

Applicable Corporate Governance Codes

The Board has considered how the principles and provisions of The UK Corporate Governance Code 2018 ("the Code") has been applied by the Company and has reported against this Code (and the associated FRC Guidance on Audit Committees). A copy of the Code can be found at www.frc.org.uk.

The GFSC has stated in the "Finance Sector Code of Corporate Governance" ("GFSC Code") that companies which report against the UK Corporate Governance Code are deemed to meet the GFSC Code, and need take no further action.

Corporate Governance Statement

The Company has complied with the recommendations of the Code, except as set out below and elsewhere in the Corporate Governance Report.

The Chairman should not remain in post beyond nine years from the date of their first appointment to the Board.

The Chairman of the Board has been the Chairman continuously since the Company was founded 28 years ago. The shareholders have given the Chairman their approval for his re-election at every Annual General Meeting held since the Company's formation and always with a high percentage of the shareholders voting in favour of his re-election. Furthermore, the Directors have very high regard for the Chairman's integrity, professionalism, and business expertise. These considerations, combined with the excellent performance of the Company over the past 28 years, are key in the overwhelming support the Chairman has received from shareholders and Directors to continue in his role.

Listing Rule 9.8.6R (9)(a)

While the Board recognises that diversity, including gender and ethnic diversity, is of material importance to both its own shareholders and that of wider society, the Board composition at present does not meet the following target requirements of Listing Rule 9.8.6R (9)(a):

- a) At least 40% of individuals on its board are women;
- b) At least one of the senior board positions is held by a woman; and
- At least one individual on its board is from a minority ethnic background.

There is a formal, rigorous and transparent procedure for the appointment of new Directors. Candidates are identified and selected on merit against objective criteria and with due regard to the benefits of diversity on the Board.

The Board has not adopted a diversity policy in respect of age or nationality, believing that prescriptive targets would not be appropriate for, or in the interests of the Company and its shareholders. Instead the Board focusses on encouraging diversity of business skills and experience recognising that Directors with diverse skills sets, capabilities and experience gained from different backgrounds enhance the Board. The Board considers that its members have a balance of skills and experience which are relevant to the Company and remains committed to the value and importance of diversity in the Boardroom.

The tables below set out the Board's current composition against the targets prescribed by Listing Rule 9.8.6R(9)(a).

	Number of board members	Percentage of the board	Number of senior positions on the Board (CEO, CFO, SID and Chair)*
Men	6	100%	Not applicable - see note* below
Women	N/A	N/A	
Not specified/prefer not to say	N/A	N/A	

^{*} The Company is not self-managed and does not have executive management functions, including roles of CEO and CFO.

of	umber board embers	Percentage of the board	Number of senior positions on the Board (CEO, CFO, SID and Chair)*
White British or other White (including minority-white groups)	6	100%	Not applicable - see note* above
Mixed/Multiple Ethnic Groups	N/A	N/A	
Asian/Asian British	N/A	N/A	
Black/African/ Caribbean/Black British	N/A	N/A	
Other ethnic group, including Arab	N/A	N/A	
Not specified/ prefer not to say	N/A	N/A	

Remuneration Committee

The Board has not deemed it necessary to appoint a Remuneration Committee as, being comprised of a majority of independent Directors; the whole Board considers these matters on an ongoing basis.

Executive Directors' remuneration

As the Board has no executive Directors, it is not required to comply with the principles of the Code in respect of executive Directors' remuneration.

Directors' fees are detailed in the Directors' Remuneration Report on page 37.

Internal audit function

As the Company delegates to third parties its day-to-day operations and has no employees, the Board has determined that there is no requirement for an internal audit function. The Directors consider the ability to place reliance on third party service providers and reports therefrom and review annually whether a function equivalent to an internal audit is needed and will continue to monitor its systems of internal controls in order to provide assurance that they operate as intended.

The Company complies with the corporate governance statement requirements pursuant to the FCA's Disclosure Guidance and Transparency Rules by virtue of the information included in the Corporate Governance section of the Annual Report together with information contained in the Strategic Report and the Directors' Report.

As the Company does not have any employees, the Board or Audit Committee have not established arrangements by which staff of the Company may, in confidence, raise concerns about possible improprieties in matters of financial reporting or other matters.

Directors

Nigel Cayzer (Chairman)

British

Nigel Cayzer is Chairman of Aberdeen Asian Smaller Companies Investment Trust PLC. He is also a Director of a number of private companies. He has been Chairman or a Director of a number of Investment Companies and was Chairman of Maggie's, a leading cancer charity, from 2005 until 2014.

Sidney Cabessa

French

Sidney Cabessa is also a Director of Club-Sagem and Mercator/Nature et découvertes. He was Chairman of CIC Finance, an Investment Fund and a subsidiary of French banking group, CIC- Credit Mutuel and was previously a Director of other investment companies. He has previously been Senior Adviser with Rothschild and Co (2012 to 2017); and is now Senior Adviser at Essling Capital. He is also a Director of Harwood Capital Management Limited.

Jamie Brooke (Appointed 15 September 2022) British

Jamie Brooke is a qualified Chartered Accountant with over 25 years investment experience and has been a director on over 20 Boards. He was formerly lead fund manager for the Hanover Catalyst Fund, prior to which he was at Lombard Odier where as a fund manager, he specialised in strategic UK small cap equity investing, having moved with the Volantis team from Henderson Global, and before that, Gartmore. He is currently a nonexecutive Director at Chapel Down Group plc and Flowtech Fluidpower plc.

Gavin Farrell (Appointed 15 September 2022)

British

Gavin Farrell qualified as a Solicitor of the Supreme Court of England and Wales, a French Avocat and an Advocate of the Royal Court of Guernsey. He worked for a number of years at Simmons & Simmons in their London and Paris offices, both in the general corporate and financial services/funds departments. He then moved to Guernsey in 1999 where he was called as an Advocate of the Royal Court of Guernsey. Mr Farrell became a partner in January 2003 of the corporate department of the then Ozannes, which became Mourant Ozannes where he ended as a senior partner and head of the Corporate Department. He left Mourant Ozannes in November 2016 to be one of the founding partners of Ferbrache & Farrell LLP. He holds a number of directorships in both public and private investment funds, captive insurance companies, active management entities and trading groups. He is a resident of Guernsey.

Christopher Mills

British

Christopher Mills is a Partner and the Chief Executive Officer of Harwood Capital LLP. He is also Chief Investment Officer of NASCIT. NASCIT is the winner of numerous Micropal and S&P Investment Trust awards. In addition, he is a non-executive Director of numerous UK companies which are either currently, or have in the past five years been, publicly quoted.

John Grace

New Zealander

John Grace is actively involved in the management of several global businesses including asset management, financial services, and real estate. He is a Director and Founder of Sterling Grace International Ltd. Sterling Grace and its affiliates manage investments for high net-worth investors, institutions and

investment partnerships. The Company is active in global money management, financial services, private equity and real estate investments. He is also Chairman of Trustees Executors Holdings Ltd, owner of the premier and oldest New Zealand trust Company established in 1882. It is the market leader in the corporate trust business. Its clients include government divisions, corporations and banks. The Company is active in wholesale financial services including trust accounting, securities custody and mutual fund registry. It is also actively engaged in the personal trust business. He graduated from Georgetown University. He has served as a Director of numerous public companies and charities. He currently supports genetic research and education initiatives in science at the University of Lausanne, EPFL École polytechnique fédérale de Lausanne and CERN, the European Organization for Nuclear Research.

John Radziwill

British

John Radziwill is currently a Director of StoneX Group Inc. (known as INTL FCStone Inc. up to 5 July 2022), Goldcrown Group Limited, Fourth Street Capital Ltd, Fifth Street Capital Ltd and Netsurion Ltd. In the past ten years, he also served as a Director of Acquisitor Plc and Acquisitor Holdings (Bermuda) Ltd, Air Express International Corp., Radix Ventures Inc, Baltimore Capital Plc, Lionheart Group Inc, USA Micro Cap Value Co Ltd and Radix Organisation Inc. Mr Radziwill is a member of the Bar of England and Wales.

Former Directors

Rupert Evans and Walid Chatila, who were both nonexecutive Directors of the Company, resigned as Directors effective 15 September 2022.

Our Governance Framework

Chairman

Nigel Cayzer

Responsibilities:

The leadership, operation and governance of the Board, ensuring effectiveness, and setting the agenda for the Board.

The Board Members of Oryx International Growth Fund Limited:

Nigel Cayzer (Chairman), Sidney Cabessa, Jamie Brooke, Gavin Farrell, John Grace, Christopher Mills and John Radziwill.

The Board members, except for Christopher Mills who is a Partner of the Investment Manager and Sidney Cabessa who is a Director of Harwood Capital Management Limited, are all independent Directors.

Additionally, the Board members are all non-executive Directors.

Responsibilities:

Overall conduct of the Company's business and setting the Company's strategy.

More details below.

Nomination Committee

Nigel Cayzer (Chairman)

Members:

Sidney Cabessa
John Grace
John Radziwill
Walid Chatila (Resigned, 15 September 2022)
Rupert Evans (Resigned, 15 September 2022)

The Nomination Committee currently comprises of four independent non-executive Directors. Walid Chatila and Rupert Evans, resigned during the year have not been replaced in the Nomination Committee.

Responsibilities:

To ensure the Board comprises individuals with the necessary skills, knowledge and experience to ensure that the Board is effective in discharging its responsibilities and oversight of all matters relating to corporate governance.

More details on pages 31 and 32.

Audit Committee

Members:

Jamie Brooke (Chairman, Appointed, 15 September 2022) John Radziwill

Walid Chatila (Resigned, 15 September 2022) Rupert Evans (Resigned, 15 September 2022

The Audit Committee currently comprises of two independent non-executive Directors, this follows the resignation of Walid Chatila and Rupert Evans and the appointment of Jamie Brooke, a former Director of the Company. Gavin Farrell will be appointed to the Audit Committee upon gaining sufficient experience as a Director of the Company.

Responsibilities:

The provision of effective governance over the appropriateness of the Company's financial reporting including the adequacy of related disclosures, the performance of the external auditors, and the management of the Company's systems of internal financial and operating controls and business risks.

More details on pages 33 to 36.

Board Independence and Composition

The Board

The Board is comprised of five independent nonexecutive Directors including the Chairman Nigel Cayzer and two non-independent non-executive Directors, Christopher Mills who is an employee of the Investment Manager and Sidney Cabessa who is a Director of Harwood Capital Management Limited. The biographical details of the Directors holding office at the date of this report are listed on pages 24 and 25 demonstrate a breadth of investment, accounting and professional experience. The Board does not consider it necessary to appoint a Senior Independent Director, as it is considered that all the Directors have different qualities and areas of expertise on which they may lead where issues arise and to whom concerns can be conveyed. The performance of the Company is considered in detail at each Board meeting. An evaluation of Directors' performance, their independence and the work of the Board as a whole and its committees is reviewed annually by the Nomination Committee. The Directors also review the Chairman's performance, without the Chairman present. The Board considers that independence is not compromised by the length of tenure and that it has the appropriate balance of skills, experience, ages and length of service in the circumstances. The majority of the Board is considered to be independent.

The Investment Manager takes decisions as to the purchase and sale of individual investments. The Directors have access to the advice and services of the Company Secretary through its appointed representatives who are responsible to the Board for ensuring that Board procedures are followed and that applicable rules and regulations are complied with.

Directors are able to have access to independent professional advice at the Company's expense if they judge it necessary to discharge their responsibilities as Directors. To enable the Board to function effectively and allow Directors to discharge their responsibilities, full and timely access is given to all relevant information.

The Company Secretary, BNP Paribas S.A., Guernsey Branch through its representative, acts as Secretary to the Board and Committees and in doing so it:

- assists the Chairman in ensuring that all Directors have full and timely access to all relevant documentation;
- · organises induction of new Directors; and
- is responsible for ensuring that the correct Board procedures are followed and advises the Board on corporate governance matters.

The Culture and Values of the Board

The Board is comprised of seven male Directors from four different nationalities and with diverse backgrounds and skill sets in key areas including investment, business management, accountancy, finance and law. The culture of the Board is to discuss all matters in an open and professional manner. All members of the Board have proven competence and a history of success in their business ventures and careers. All are well regarded in their communities and all acknowledge the responsibility placed on them and the need to be ethical, professional and assertive in executing their duties.

Directors' Appointment and Re-election

	Date of	
Director	Appointment	
Nigel Cayzer	3 December 1994	
Sidney Cabessa	3 June 2003	
Jamie Brooke	15 September 2022	
Gavin Farrell	15 September 2022	
John Grace	8 March 2011	
Christopher Mills	3 December 1994	
John Radziwill	1 May 2007	

No Director has a service contract with the Company. Any Director may resign in writing to the Board at any time.

In accordance with the Code, all Directors seek annual re-election to the Board at the AGM.

The Board continues to believe that Mr Cayzer, Mr Brooke, Mr Farrell, Mr Radziwill and Mr Grace are independent and that all Directors standing for reelection make an effective and valuable contribution to the Board and that the Company should support their re-election.

Responsibilities

The Board meets at least four times each year and deals with the important aspects of the Company's affairs including the setting and monitoring of investment strategy, and the review of investment performance. The Investment Manager takes decisions as to the purchase and sale of individual investments, in line with the investment policy and strategy set by the Board. The Investment Manager together with the Company Secretary also ensures that all Directors receive, in a timely manner, all relevant management, regulatory and financial information relating to the Company and its portfolio of investments. A representative of the Investment Manager attends each quarterly Board meeting,

enabling Directors to question any matters of concern or seek clarification on certain issues. Matters specifically reserved for decision by the full Board have been defined and a procedure adopted for Directors in the furtherance of their duties to take independent professional advice at the expense of the Company.

Tenure

The Board has adopted a policy on tenure that is considered appropriate for an investment Company. The Board does not believe that length of service, by itself, leads to a closer relationship with the Investment Manager or necessarily affects a Director's independence. The Board's tenure and succession policy seeks to ensure that the Board is well-balanced and will be refreshed from time to time by the appointment of new Directors with the skills and experience necessary to replace those lost by Directors' retirements. Directors must be able to demonstrate their commitment to the Company. The Board seeks to encompass relevant past and current experience of various areas relevant to the Company's business.

Relationship with the Investment Manager and the Administrator

The Board has delegated various duties to external parties including the management of the investment portfolio, the custodian services (including the safeguarding of assets), the registration services and the day-to-day Company secretarial, administration and accounting services.

The Board receives and considers reports regularly from the Investment Manager and ad hoc reports and information are supplied to the Board as required. The Investment Manager takes decisions as to the purchase and sale of individual investments. The

Investment Manager and Administrator also ensure that all Directors receive, in a timely manner, all relevant management, regulatory and financial information. Representatives of the Investment Manager and Administrator attend each Board meeting enabling the Directors to probe further on matters of concern. A formal schedule of matters specifically reserved for decision by the full Board has been defined and a procedure adopted for Directors. The Directors have access to the advice and service of the corporate Company Secretary through its appointed representative who is responsible to the Board for ensuring that Board procedures are followed and that applicable rules and regulations are complied with.

Article 22(2)(e) & (f) of AIFMD requires the disclosure of fixed and variable remuneration paid by the AIFM to senior management and members of staff of the AIFM whose actions have a material impact on the risk profile of the AIF. The AIFM consider the actions of only one member, of senior management, to have a material impact on the risk profile of the Company. Therefore, the Directors do not consider it appropriate to make this disclosure.

Shareholder Engagement Communications with Shareholders

The Board believes that the maintenance of good relations with shareholders is important for the long-term prospects of the Company. Where appropriate the Chairman, and other Directors are available for discussion about governance and strategy with major shareholders and the Chairman ensures communication of shareholders' views to the Board. The Board receives feedback on the views of shareholders from the Investment Manager and Broker.

The Board believes that the AGM provides an appropriate forum for investors to communicate with the Board, and encourages participation. The AGM will be attended by at least one Director. Details of proxy votes received in respect of each resolution will be made available to shareholders at the meeting and will be posted on the Company's website following the meeting.

The Annual and Half-year Reports are available to all shareholders. The Board considers the format of the annual and interim reports so as to ensure they are useful to all shareholders and others taking an interest in the Company. In accordance with best practice, the Annual Report, including the Notice of the AGM, will be sent to shareholders at least 20 working days before the meeting.

Institutional Investors - use of voting rights

The Investment Manager, in the absence of explicit instructions from the Board, are empowered to exercise discretion in the use of the Company's voting rights in respect of investments and then to report to the Board, where appropriate, regarding decisions taken. The Board has considered whether it was appropriate to adopt a voting policy and an investment policy with regard to social, ethical and environmental issues and concluded that it was not appropriate to change the existing arrangements.

2023 Annual General Meeting

The AGM will be held in Guernsey in August 2023. The notice for the AGM set out in the Shareholder Circular accompanying this Annual Report sets out the ordinary and special resolutions to be proposed at the meeting. Separate resolutions are proposed for each substantive issue.

Conflict of Interests

Directors are required to disclose all actual and potential conflicts of interest to the Board as they arise for consideration and the Board may impose restrictions or refuse to authorise conflicts if deemed appropriate. The Directors have undertaken to notify the Company Secretary as soon as they become aware of any new potential conflicts of interest that would need to be approved by the Board. Only Directors who have no material interest in the matter being considered will be able to participate in the Board approval process.

It has also been agreed that the Directors will advise the Chairman and the Company Secretary in advance of any proposed external appointment. None of the Directors, except Christopher Mills, had a material interest in any contract, which is significant to the Company's business. Note 18 provides further details on the material interests of Christopher Mills. The Directors' Remuneration Report on pages 37 and 38 provides information on the remuneration and interests of the Directors.

Performance Evaluation

The Board has adopted a formal annual evaluation of its own performance and that of its Committees and individual Directors. The last evaluation took place in 2023 and was led by the Chairman. The Chairman was not involved in the evaluation of his own performance.

The evaluation is conducted utilising a questionnaire. The Board has developed criteria for use at the evaluation, which focuses on the individual contribution to the Board and its Committees made by each Director and the Chairman, each Director's independence and the responsibilities, composition and agenda of the Committees and of the Board itself.

A review of Board composition and balance, including succession planning for appointments to the Board, is included as part of the annual performance evaluation. The non-executive Directors also meet without the Chairman present to appraise his performance.

During the annual Board evaluation in 2023, it was concluded that all Directors with the exception of Messer's Mills and Cabessa were independent. It was confirmed that the Chairman and all Directors felt well prepared and able to participate fully at Board meetings, with a good understanding of the markets and investments of the Company. It was agreed that all relevant topics were fully discussed at effective Board meetings, with the Board having a good range of competencies and skills.

The Board will continue to review its procedures, its effectiveness and development in the year ahead.

Induction/Information and Professional Development

Directors are provided, on a regular basis, with key information on the Company's policies, regulatory requirements and its internal controls. Regulatory and legislative changes affecting Directors' responsibilities are advised to the Board as they arise, along with changes to best practice from, amongst others, the Company Secretary and the Auditor. Advisers to the Company also prepare reports for the Board from time to time on relevant topics and issues.

When a new Director is appointed to the Board, they will be provided with all relevant information regarding the Company and their respective duties and responsibilities as a Director. In addition, a new Director will also spend time with representatives of the Investment Manager in order to learn more about

their processes and procedures. This process was followed in the current year upon appointment of Jamie Brooke and Gavin Farrell, effective from 15 September 2022, as non-executive Directors of the Company.

Independent Advice

The Board recognises that there may be occasions when one or more of the Directors feels it is necessary to take independent legal advice at the Company's expense. A procedure has been adopted to enable them to do so, which is managed by the Company Secretary.

Directors' Indemnity

To the extent permitted by Guernsey law, the Company's Articles of Incorporation provide an indemnity for the Directors against any liability except such (if any) as they shall incur by or through their own breach of trust, breach of duty or negligence.

During the year the Company has maintained insurance cover for its Directors and Officers under a Directors' and Officers' liability insurance policy.

Board Meetings

The Board meets at least quarterly. Certain matters are considered at all Board meetings including the performance of the investments, NAV and share price and associated matters such as asset allocation and investor relations. Consideration is also given to administration, compliance and corporate governance matters, and where applicable, reports are received from the Board committees.

Directors unable to attend a Board meeting are provided with the Board papers and can discuss issues

arising in the meeting with the Chairman or another non-executive Director.

Attendance at scheduled meetings of the Board and its committees for the year ended 31 March 2023

	Board	Audit Committee	Nomination Committee
Number of meetings			
during the year	4	3	1
Nigel Cayzer	4	n/a	1
Sidney Cabessa	3	n/a	ı nil
Walid Chatila*	2	1	n/a
Rupert Evans*	2	1	n/a
Christopher Mills	4	n/a	n/a
Jamie Brooke**	3	2	n/a
Gavin Farrell**	3	n/a	n/a
John Grace	3	n/a	ı 1
John Radziwill	4	3	1

^{*} Rupert Evans and Walid Chatila, who were both nonexecutive Directors of the Company, resigned as Directors effective 15 September 2022.

Board Committees

The Board has established a Nomination and an Audit Committee with defined terms of reference and duties. Further details of these committees can be found below and up to page 36. The terms of reference for each committee can be found on the Company's website www.oryxinternationalgrowthfund.co.uk.

Nomination Committee

Membership:

Nigel Cayzer - Chairman (Independent non-executive Director)

Sidney Cabessa (Non-executive Director)

John Grace (Independent non-executive Director)

John Radziwill (Independent non-executive Director)

Walid Chatila (Independent non-executive Director,
resigned 15 September 2022)

Rupert Evans (Independent non-executive Director, resigned 15 September 2022)

The Board believes it is appropriate for the Company Chairman to also be Chairman of the Nomination Committee as he is an independent non-executive Director.

Key Objectives

To evaluate the effectiveness of the Board and its Committees and to evaluate the balance of skills, knowledge and experience on the Board and the division of responsibilities between the Board and the Investment Manager. The Nomination Committee also meets as and when appropriate to replace Directors who retire from the Board, leading the process for Board appointments and making recommendations to the Board.

Responsibilities

- Regularly reviews and makes recommendations in relation to the structure, size and composition of the Board including the diversity and balance of skills, knowledge and experience, and the independence of the non-executive Directors;
- Oversees the performance evaluation of the Board, its committees and individual Directors;

^{**} Jamie Brooke and Gavin Farrell were appointed as non-executive Directors of the Company effective 15 September 2022.

- Reviews the tenure of each of the non-executive Directors;
- Leads the process for identifying and making recommendations to the Board regarding candidates for appointment as Directors, giving full consideration to succession planning and the leadership needs of the Company;
- Makes recommendations to the Board on the composition of the Board's committees; and
- Is responsible for the oversight of all matters relating to corporate governance, bringing any issues to the attention of the Board.

Nomination Committee Meetings

Only members of the Nomination Committee have the right to attend Committee meetings. Representatives of the Investment Manager and Administrator are invited by the Nomination Committee to attend meetings as and when appropriate. In the event of matters arising concerning an individual's membership of the Board, they would absent themselves from the meeting as required and another independent non-executive Director would take the Chair, if this applied to the Committee Chairman.

Main Activities during the Year

On 31 March 2022, the nomination committee proposed the appointment of Jamie Brooke, based on his knowledge of the Company's affairs and the underlying asset class, as a former Director of the Company. The nomination committee also proposed the appointment of Gavin Farrell, based on his knowledge of Guernsey's legal, regulatory and governance environment and his expertise in investment funds. The nomination committee made a formal recommendation to the Board that Jamie Brooke and Gavin Farrell be appointed as Directors of the Company.

On 15 September 2022, the Board agreed with these recommendations and Jamie Brooke and Gavin Farrell were appointed as Directors of the Company with effect from 15 September 2022.

The Nomination Committee also met to consider and review the results of the annual Board evaluation and considered that the balance of experience, skills, independence and knowledge of the Company was appropriate. Refer to pages 22 and 23 for further details.

Nigel Cayzer On behalf of the Nomination Committee 5 July 2023

Audit Committee Report

Audit Committee

Membership:

Jamie Brooke - Chairman (Independent nonexecutive Director, appointed 15 September 2022) John Radziwill (Independent non-executive Director) Walid Chatila (Independent non-executive Director, resigned 15 September 2022)

Rupert Evans (Independent non-executive Director, resigned 15 September 2022)

Key Objectives

The provision of effective governance over the appropriateness of the Company's financial reporting including the adequacy of related disclosures, the performance of the external auditors, and the management of the Company's systems of internal financial and operating controls and business risks.

Responsibilities

- Reviewing the Company's internal financial controls;
- Reviewing the Company's financial results announcements, financial statements and monitoring compliance with relevant statutory and listing requirements;
- Reporting to the Board on the appropriateness of the Company's accounting policies and practices including critical accounting policies and practices;
- Advising the Board on whether the Audit
 Committee believes the annual report and
 financial statements, taken as a whole, are fair,
 balanced and understandable and provides the
 information necessary for shareholders to assess
 the Company's performance;

- Overseeing the relationship with the external auditor;
- Considering the financial and other implications on the independence of the auditor arising from any non-audit services provided by the auditors; and
- Compile a report on its activities to be included in the Company's annual report.

The Committee members have a wide range of financial and commercial expertise necessary to fulfil the Committee's duties.

Audit Committee Meetings

The Committee meets at least three times a year. Only members of the Audit Committee have the right to attend Audit Committee meetings. Representatives of the Investment Manager and Administrator will be invited to attend Audit Committee meetings on a regular basis and other non-members may be invited to attend all or part of the meeting as and when appropriate and necessary. The Company's external auditor, is also invited whenever it is appropriate. The Committee is also able to meet separately with the external auditors without the Investment Manager being present.

Main Activities during the Year

The Committee assists the Board in carrying out its responsibilities in relation to financial reporting requirements, risk management and the assessment of internal financial and operating controls. It also manages the Company's relationship with the external auditor. Meetings of the Committee generally take place prior to a Company Board meeting. The Committee reports to the Board, as part of a separate agenda item, on the activity of the Committee and

Audit Committee Report (continued)

matters of particular relevance to the Board in the conduct of their work.

The Committee advises the Board on whether it believes the annual report and financial statements, taken as a whole, are fair, balanced and understandable and provides the information necessary for shareholders to assess the Company's performance, business model and strategy. The Committee's terms of reference can be found on the Company's website

http://www.oryxinternationalgrowthfund.co.uk.

At its meetings during the year, the Committee focused on:

Financial Reporting

The primary role of the Committee in relation to financial reporting is to review in conjunction with the Investment Manager and the Administrator the appropriateness of the half-year and the audited annual financial statements concentrating on, amongst other matters:

- The quality and acceptability of accounting policies and practices;
- The clarity of the disclosures and compliance with financial reporting standards and relevant financial and governance reporting requirements;
- Material areas in which significant judgements have been applied or there has been discussion with the external auditor;
- Whether the annual report and financial statements, taken as a whole, are fair, balanced and understandable and provides the information necessary for shareholders to assess the

Company's performance, business model and strategy; and

 Any correspondence from regulators in relation to the quality of our financial reporting.

To aid its review, the Committee considers reports from the Investment Manager, Administrator and also reports from the external auditor on the outcome of their annual audit.

Significant Accounting Matters

In relation to the annual report and financial statements for the year ended 31 March 2023, the following significant issues were considered by the Audit Committee:

Significant Area

Valuation of Investments

How Addressed

The Board periodically receive a report from the Investment Manager on the valuation of the portfolio and on the assumptions used in valuing the unlisted assets in the portfolio. The Board regularly analyses the investment portfolio of the Company in terms of investment mix, fair value hierarchy and valuation. The Board has held discussions with the Investment Manager with regards to the methodology used in valuing the unlisted assets in the portfolio. The Board has considered the risk due to the war in Ukraine in detail as part of its periodic viability and risk assessments.

Based on their review and analysis, the Board is satisfied with the valuation of the investments.

Audit Committee Report (continued)

Internal Controls

The Board is responsible for the Company's system of internal control and for reviewing its effectiveness, which was in place up to the date the financial statements were signed. The Board has delegated the responsibility of regularly reviewing the effectiveness of the systems of internal controls in place to the Audit Committee. The Audit Committee believes that the key risks identified and implementation of the system to monitor, and manage those risks, are appropriate to the Company's business as an investment Company.

The ongoing risk assessment includes the monitoring of the financial, operational and compliance risks as well as an evaluation of the scope and quality of the system of internal control adopted by the third party service providers. The Audit Committee regularly reviews the delegated services to ensure their continued competitiveness and effectiveness. The system is designed to ensure regular communication of the results of monitoring by the third parties to the Board and the incidence of any significant control failings or weaknesses that have been identified and the extent to which they have resulted in unforeseen outcomes or contingences that may have a material impact on the Company's performance or operations. The Audit Committee believes that, although robust, the Company's system of internal controls is designed to manage rather than eliminate the risk of failure to achieve business objectives.

The Committee is responsible overall for the Company's system of internal financial and operating controls and for reviewing its effectiveness. Such a system, however, is designed to manage rather than eliminate risks of failure to achieve the Company's business objectives and can only provide reasonable and not absolute assurance against material

misstatement or loss. The Board receives each year a report from the Administrator on its internal controls which includes a report from the Administrator's auditors on the control policies and procedures in operation.

The Investment Manager has established an internal control framework to provide reasonable but not absolute assurance on the effectiveness of the internal controls operated on behalf of its clients. The effectiveness of the internal controls is assessed by the Investment Manager's compliance and risk department on an ongoing basis.

In respect of the Company's system of internal controls and reviewing its effectiveness, the Directors are satisfied that a robust assessment of the principal and emerging risks facing the Company has been carried out (as outlined above) and that having reviewed the effectiveness of the risk management and internal control systems including material financial, operational and compliance controls (including those relating to the financial reporting process) no significant failings or weaknesses were identified.

External Audit

The effectiveness of the external audit process is dependent on appropriate audit risk identification at the start of the audit cycle. The Committee received a detailed audit plan from RSM CI (Audit) Limited identifying their assessment of the Key Audit Matters, being the ownership and valuation of investments. This is consistent with the Committee's own assessment which have been kept under review throughout the year. The Committee assess the effectiveness of the audit process in addressing these matters through the reporting received from RSM CI (Audit) Limited in relation to the year-end. In

Audit Committee Report (continued)

addition, the Committee seeks feedback from the Investment Manager and the Administrator on the effectiveness of the audit process. For the 2023 financial year, the Committee was satisfied that there had been appropriate focus and challenge on the significant and other key areas of audit risk and assessed the quality of the audit process to be good.

Independence

The Committee considers the independence of the external auditor on an annual basis. In its assessment of the independence of the external auditors, the Committee receives details of any relationships between the Company and RSM CI (Audit) Limited that may have a bearing on their independence and receives confirmation that the external auditor is independent of the Company.

Non Audit Services

The external auditor and the Directors have agreed a policy for non-audit services. All non-audit services are prohibited.

Auditor's Remuneration

The Committee approved the fees for audit services for 2022/23 after a review of the level and nature of work to be performed, and after being satisfied by RSM CI (Audit) Limited that the fees were appropriate for the scope of the work required. The external auditor will be remunerated £62,500 for their services to be rendered in 2022/23. This entire amount relates to the 2023 year-end audit.

Committee Evaluation

The Committee's activities formed part of the Board evaluation performed in the year. Details of this process can be found under "Performance evaluation" on page 29.

Jamie Brooke Chairman of the Audit Committee 5 July 2023

Directors' Remuneration Report

The Directors' remuneration for the year is as follows:

Director	Year Ended 31 March 2023 £	Year Ended 31 March 2022 £
Nigel Cayzer	27,500	27,500
Sidney Cabessa	20,000	20,000
Walid Chatila*	11,438	25,000
Rupert Evans*	9,205	20,000
Christopher Mills	20,000	20,000
Jamie Brooke**	13,562	-
Gavin Farrell**	10,795	-
John Grace	20,000	20,000
John Radziwill	20,000	20,000

^{*} Rupert Evans and Walid Chatila, who were both nonexecutive Directors of the Company, resigned as Directors effective 15 September 2022.

Remuneration Policy

The determination of the Directors' fees is a matter dealt with by the Board. The Directors reviewed the fees paid to the Boards of Directors of similar investment companies during 2016 and revised the remuneration of the Directors in 2017. No Director is involved in decisions relating to their own remuneration.

No Director has a service contract with the Company and Directors' appointments may be terminated at any time by one month's written notice with no compensation payable at termination.

The Company's policy is for the Directors to be remunerated in the form of fees, payable quarterly in arrears. No Director has any entitlement to a pension, and the Company has not awarded any share options

or long-term performance incentives to any of the Directors. No element of the Directors' remuneration is performance related. Directors are authorised to claim reasonable expenses from the Company in relation to the performance of their duties.

The Company's policy is that the fees payable to the Directors should reflect the time spent by the Board on the Company's affairs and the responsibilities borne by the Directors and should be sufficient to enable high calibre candidates to be recruited. During the year ended 31 March 2023, the policy was for the Chairman of the Board and the Audit Committee to be paid higher fees than the other Directors in recognition of their more onerous role and more time spent. The Board may amend the level of remuneration paid within the limits of the Company's Articles of Incorporation.

Service Contracts and Policy on Payment of Loss of Office

Directors are appointed with the expectation that they are initially appointed until the following AGM when, it is required that they be re-elected by shareholders. Directors will initially serve for a period of three years, and will stand for re-election every three years. In accordance with the Code, Directors who have served for more than nine years as non-executive Directors will retire annually and seek re-election to the Board. Directors or members of the Investment Manager are subject to annual election, inaccordance with Listing Rule 15.2.13A.

The biographies of the Directors holding office at the date of this report are provided on pages 24 and 25.

Directors' Interests

The Company has not set any requirements or guidelines for Directors to own shares in the Company.

^{**} Jamie Brooke and Gavin Farrell were appointed as non-executive Directors of the Company effective 15 September 2022.

Directors' Remuneration Report (continued)

The beneficial interests of the Directors and their connected persons in the Company's shares are shown in the table below:

	31 March 2023 Ordinary Shares	31 March 2022 Ordinary Shares
Christopher Mills	350,000	350,000
John Grace*	130,000 346,607	130,000 346,607
Jamie Brooke	2,000	-

^{*} John Grace holds a beneficial interest of 130,000 Ordinary Shares. Mr John Grace is also a member of a class of beneficiaries which holds an interest in 346,607 Ordinary Shares.

Christopher Mills is a Partner and Chief Executive
Officer of Harwood Capital LLP and a Director of
Harwood Capital Management (Gibraltar) Limited, the
Company's Investment Manager. Harwood Capital
Management (Gibraltar) Limited is entitled to fees as
detailed in notes 4 and 6 of the financial statements.

No fees were paid or are payable to Harwood Capital Management Limited where Sidney Cabessa is a Director.

Other than fees payable in the ordinary course of business, there have been no material transactions with these related parties.

Annual Report on Remuneration

Other than as shown on page 37, no other remuneration or compensation was paid or payable by the Company during the year to any of the Directors.

Advisers to the Remuneration Committee

The Board has not sought the advice or services by any outside person in respect of its consideration of the Directors' remuneration.

Nigel Cayzer On behalf of the Board 5 July 2023

Statement of Directors' Responsibilities in Respect of the Annual Report and the Financial Statements

The Directors are responsible for preparing the Annual Report and financial statements in accordance with applicable law and regulations.

The Companies (Guernsey) Law, 2008 (as amended) requires the Directors to prepare financial statements for each financial year. Under that law they are required to prepare the financial statements in accordance with International Financial Reporting Standards (IFRS) as adopted by the UK and applicable law.

Under Company law the Directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of its profit or loss for that period. In preparing these financial statements, the Directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable, relevant and reliable;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- assess the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern; and
- use the going concern basis of accounting unless they either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.

The Directors are responsible for keeping proper accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and enable them to ensure that its financial statements comply with the Companies (Guernsey) Law, 2008. They are responsible for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error, and have general responsibility for taking such steps as are reasonably open to them to safeguard the assets of the Company and to prevent and detect fraud and other irregularities.

The Directors are responsible for the maintenance and integrity of the corporate and financial information included on the Company's website. Legislation in Guernsey governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Responsibility statement of the Directors in respect of the Annual Report and financial statements

We confirm that to the best of our knowledge:

- the financial statements, prepared in accordance with the applicable set of accounting standards, give a true and fair view of the assets, liabilities, financial position and profit or loss of the Company; and
- the Annual Report includes a fair review of the development and performance of the business and the position of the issuer, together with a description of the principal and emerging risks and uncertainties that they face.

Statement of Directors' Responsibilities in Respect of the Annual Report and the Financial Statements (continued)

We consider the Annual Report and financial statements, taken as a whole, is fair, balanced and understandable and provides the information necessary for shareholders to assess the Company's position and performance, business model and strategy.

By order of the Board

Jamie BrookeGavin FarrellDirectorDirector5 July 20235 July 2023

Opinion

We have audited the financial statements of Oryx International Growth Fund Limited (the "Company"), which comprise the statement of financial position as at 31 March 2023, and the statement of comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes 1 to 20 to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and International Financial Reporting Standards as adopted by the United Kingdom.

In our opinion the financial statements of the Company:

- give a true and fair view of the state of the Company's affairs as at 31 March 2023 and of its loss for the year then ended;
- have been properly prepared in accordance with IFRS as adopted by the United Kingdom ('IFRS');
 and
- have been prepared in accordance with the Companies (Guernsey) Law, 2008.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) ('ISAs (UK)') and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in Guernsey, including the FRC's Ethical Standard as applied to listed public interest entities, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we

have obtained is sufficient and appropriate to provide a basis for our opinion.

Our approach to the audit

Our audit was scoped by obtaining an understanding of the Company and its environment, including internal control, and assessing the risks of material misstatement.

Our consideration of the control environment The Company has appointed BNP Paribas S.A., Guernsey Branch to provide the accounting function. The accounting function has been delegated to BNP Paribas S.A., Jersey Branch ('BNP'). We have obtained BNP's ISAE 3402 controls assurance report for the period 1 October 2021 to 31 October 2022 which summarises the suitability of design and implementation and operating effectiveness of controls. We have reviewed the report and considered the controls relevant to the accounting functions undertaken by BNP for the Company. As the reporting date of the Company is 31 March 2023, we have obtained correspondence issued by BNP confirming that there have not been any material changes to the internal control environment nor any material deficiencies in the internal controls to this date.

Key audit matters

Key audit matters are those matters that, in our professional judgment, were of most significance in the audit of the financial statements and include the most significant assessed risks of material misstatement (whether or not due to fraud) identified by us, including those which had the greatest effect on: the overall audit strategy; the allocation of resources in the audit; and directing the efforts of the engagement team. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. In arriving at our audit opinion, the key audit matter was as follows:

Key Audit Matter

Ownership and valuation of Investments

The Company's investments (see note 10 and the investment schedule within the Strategic Report) are included at fair value of £193,040,511 (2022: £208,887,876). The portfolio is made up of listed and unlisted investments.

Listed investments (95% of total investment value (2022: 96%))

Listed investments are actively traded on recognised markets which are measured at fair value based on market prices and other prices determined with reference to observable inputs.

Although all of the listed investments have quoted market pricing data available which is used to value the investments, there is a risk of material misstatement that the investments may be incorrectly valued due to stale prices, low trading volumes or errors reported in third party prices. Where investments are not regularly traded there is a greater risk of material misstatement that the quoted price is not reflective of fair value and this should be taken into consideration in the directors' assessment. Valuation has a significant impact on the net asset value of the Company.

There is a risk that listed investments are not directly owned by the Company.

All listed investments (with the exception of Carr's Group PLC) are held by the Custodian. Ensuring that the Custodian records all the investments correctly under the Company's name is critical since the listed investment portfolio represents the principal element of the financial statements, being the single largest asset on the Statement of Financial Position.

How our scope addressed this matter

Our procedures on the valuation of listed investments included:

- understanding the relevant controls around listed valuation;
- testing 100% of the valuations of listed investments by agreeing the prices directly to independent third party sources;
- considering the trading history of listed investments to determine whether they have been frequently traded, and volumes at which they have been traded to consider whether the year end prices are stale.

Our procedures on ownership of listed investments included:

- obtaining an understanding of the relevant controls around custody of listed investments by reviewing the ISAE 3402 controls assurance report of the custodian; and
- agreeing the holdings to independent third party confirmation provided by the Company's custodian (with the exception of Carr's Group PLC where confirmation was obtained directly).

Key Audit Matter

Ownership and valuation of Investments (continued) Unlisted investments (5% of total investments (2022: 4%))

Unlisted investments are measured at fair value based on the International Private Equity and Venture Capital (IPEV) valuation guidelines. These valuations involve material judgements and estimation, the primary measurement techniques employed by the directors at 31 March 2023 being earnings multiples and observable price.

There is a risk that unlisted investments are not directly owned by the Company.

Unlisted investments represent a variety of financial instruments, not solely shares. Ensuring that the Company records ownership of all unlisted investments correctly is critical.

How our scope addressed this matter

Our procedures on the valuation of unlisted listed investments included:

- utilising RSM valuation specialists;
- obtaining an understanding of the Company's unlisted investments held at the year end, including attendance at valuation meetings with the investment manager and reviewing other relevant documentation;
- obtaining an understanding of and challenging the key assumptions and judgements affecting portfolio company valuations, including consideration of the appropriateness of the valuation basis and sensitivities.

Our procedures on ownership of unlisted investments included:

direct confirmation of ownership from third party

Key observations

Based on the procedures, we concluded that the ownership and valuation of investments is appropriate.

Our application of materiality

We define materiality as the magnitude of misstatement in the financial statements that makes it probable that the economic decisions of a reasonably knowledgeable person would be changed or influenced. We use materiality both in planning the scope of our audit work and in evaluating the results of our work.

Based on our professional judgement, we determined materiality for the financial statements as a whole as follows:

Materiality £3,180,000 (2022: £3,310,000).

Basis for determining materiality - Approximately 1.5% of the Company's total assets (2022: 1.5%).

Rationale for the benchmark applied - The key users of the financial statements are primarily focused on the valuation of the Company's assets.

Performance materiality

We set performance materiality at a level lower than materiality to reduce the probability that, in aggregate, uncorrected and undetected misstatements exceed the materiality for the financial statements as a whole. Performance materiality was set at 75% (2022: 75%) of materiality for the 2023 audit. In determining performance materiality, we considered our understanding of the entity, including our assessment of the overall control environment.

Error reporting threshold

We agreed with the Audit Committee that we would report to them all audit differences in excess of £150,000 (2022: £160,000), as well as differences below that threshold that, in our view, warranted

reporting on qualitative grounds. We also report to the Audit Committee on disclosure matters that we identified when assessing the overall presentation of the financial statements.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Our evaluation of the directors' assessment of the Company's ability to continue to adopt the going concern basis of accounting included our review of the directors' statement in note 2(b) and their identification of any material uncertainties to the Company's ability to continue over a period of at least twelve months from the date of approval of the financial statements.

We considered as part of our risk assessment the nature of the Company, its business model and related risks including where relevant the impact of the conflict in Ukraine, the requirements of the applicable financial reporting framework and the system of internal control.

We evaluated the directors' assessment of the Company's ability to continue as a going concern, including challenging the underlying data and key assumptions used to make the assessment, and evaluated the directors' plans for future actions in relation to their going concern assessment.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Company's ability to continue as a going concern for a period of at least twelve months from the date of approval of the financial statements.

We are required to state whether we have anything material to add or draw attention to in relation to that statement required by Listing Rule 9.8.6R(3) and report if the statement is materially inconsistent with our knowledge obtained in the audit. We confirm that we have nothing to report in connection with this matter.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the Annual Report, other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in respect of these matters.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Companies (Guernsey) Law, 2008 requires us to report to you if, in our opinion;

- adequate accounting records have not been kept; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

Corporate governance statement

The Listing Rules require us to review the directors' statement in relation to going concern, longer-term viability and that part of the Corporate Governance Statement relating to the Company's compliance with the provisions of the Listing Rule 9.8.10R(2) specified for our review.

Based on the work undertaken as part of our audit, we have concluded that each of the following elements of the Strategic Report, Directors' Report, Audit Committee Report and Statement of Directors' Responsibilities is materially consistent with the financial statements or our knowledge obtained during the audit:

- Directors' statement with regards the appropriateness of adopting the going concern basis of accounting and any material uncertainties identified set out on page 18;
- Directors' explanation as to its assessment of the entity's prospects, the period this assessment

covers and why they period is appropriate set out on page 18;

- Directors' statement on fair, balanced and understandable set out on page 40;
- Board's confirmation that it has carried out a robust assessment of the emerging and principal risks set out on pages 13 to 15;
- The section of the annual report that describes the review of effectiveness of risk management and internal control systems set out on page 35 and;
- The section describing the work of the audit committee set out on pages 33 to 36.

Responsibilities of directors

As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the Company's ability to continue as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs (UK), we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion.
 The risk of not detecting a material misstatement resulting from fraud is higher than the one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

The extent to which the audit was considered capable of detecting irregularities, including fraud Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is explained below.

The objectives of our audit are to obtain sufficient appropriate audit evidence regarding compliance with laws and regulations that have a direct effect on the determination of material amounts and disclosures in the financial statements, to perform audit procedures to help identify instances of non-compliance with other laws and regulations that may have a material effect on the financial statements, and to respond appropriately to identified or suspected non-compliance with laws and regulations identified during the audit.

In relation to fraud, the objectives of our audit are to identify and assess the risk of material misstatement of the financial statements due to fraud, to obtain sufficient appropriate audit evidence regarding the assessed risks of material misstatement due to fraud through designing and implementing appropriate responses and to respond appropriately to fraud or suspected fraud identified during the audit.

However, it is the primary responsibility of management, with the oversight of those charged with governance, to ensure that the entity's operations are conducted in accordance with the provisions of laws and regulations and for the prevention and detection of fraud.

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud, we:

- obtained an understanding of the nature of the industry and sector, including the legal and regulatory frameworks that the Company operates in and how the Company is complying those frameworks;
- inquired of management, and those charged with governance, about their own identification and assessment of the risks of irregularities, including any known actual, suspected, or alleged instances of fraud;
- discussed matters about non-compliance with laws and regulations and how fraud might occur including assessment of how and where the financial statements may be susceptible to fraud having obtained an understanding of the effectiveness of the control environment; and
- reviewed minutes of the Board and Audit Committees.

We also obtained an understanding of the legal and regulatory frameworks that the Company operates in, focusing on provisions of those laws and regulations that had a direct effect on the determination of material amounts and disclosures in the financial statements. The key laws and regulations we considered in this context included IFRS as adopted by the United Kingdom, Companies (Guernsey) Law 2008, Authorised Close Ended Investment Scheme Rules 2021, Listing and Disclosure Transparency Rules and the AIC Code of Corporate Governance. The audit procedures performed included:

- a review of the financial statement disclosures and testing to supporting documentation;
- completion of disclosure checklists to identify areas of non-compliance; and
- review of the financial statement disclosures by a specialist in the Listing and Disclosure Transparency Rules.

The area that we identified as being susceptible to material misstatement due to fraud was management override of controls. The audit procedures performed included:

- testing the appropriateness of journal entries and other adjustments;
- undertaking analytical procedures to identify unusual or unexpected relationships;
- assessing whether the judgements made in determining accounting estimates, in particular in respect of the fair value of investments, is indicative of a potential bias; and
- evaluation of the business rationale of any significant transactions that are unusual or outside the normal course of business.

Owing to the inherent limitations of an audit there is an unavoidable risk that some material misstatement of the financial statements may not be detected, even though the audit is properly planned and performed in accordance with ISAs (UK). However, the principal responsibility for ensuring that the financial statements are free from material misstatement, whether caused by fraud or error, rests with the

with the directors who should not rely on the audit to discharge those functions.

In addition, as with any audit, there remains a higher risk of non-detection of fraud, as this may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls. Our audit procedures are designed to detect material misstatement. We are not responsible for preventing non-compliance or fraud and cannot be expected to detect non-compliance with all laws and regulations.

Other matters which we are required to address

Following the recommendation of the audit committee, we were appointed by the directors on 25 March 2021 to audit the financial statements for the year ending 31 March 2021 and subsequent financial periods. The period of total uninterrupted engagement is 3 years, covering the years ended 31 March 2021 to 2023.

No non-audit services have been provided to the Company and we remain independent of the Company in conducting our audit.

Our audit opinion is consistent with our reporting to the audit committee we are required to provide in accordance with ISAs (UK).

Use of our report

This report is made solely to the Company's members, as a body, in accordance with section 262 of the Companies (Guernsey) Law, 2008. Our audit work has been undertaken so that we might state to the Company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone

other than the Company and the Company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Philip J Crosby For & on behalf of RSM CI (Audit) Limited

Chartered Accountants and Recognized Auditors Guernsey, C.I.

5 July 2023

Statement of Comprehensive Income

for the year ended 31 March 2023

	Notes	2023 £	2022 £
Income			
Dividends	3	4,850,462	2,060,399
Net realised gains on investments	10	10,606,875	35,907,323
Unrealised losses on revaluation of investments	10	(25,556,818)	(44,145,402)
Net losses on foreign currency translation		(878)	(28,860)
Other income		97,044	-
Total income		(10,003,315)	(6,206,540)
Expenses			
Investment Manager's fee	4	(2,156,129)	(2,599,302)
Directors' fees and expenses	5	(152,500)	(152,500)
Legal and professional fees		(27,323)	(18,684)
Supplementary management fee	6	(100,000)	(420,000)
Transaction costs		(130,899)	(500,604)
Administration fees	7	(170,000)	(170,000)
Audit fees		(62,500)	(59,400)
Custodian fees	8	(30,000)	(30,000)
Insurance		(10,093)	(7,380)
Registrar and transfer agent fees		(28,972)	(26,119)
Printing costs		(7,670)	(31,899)
Travel costs		(20,510)	-
Other expenses		(66,991)	(193,825)
Total expenses		(2,963,587)	(4,209,713)
Total loss for the year before taxation		(12,966,902)	(10,416,253)
Withholding tax on dividends	9	(9,242)	(9,748)
Stamp duty tax		=	(64,200)
Total loss for the year		(12,976,144)	(10,490,201)
Loss per Ordinary Share - basic and diluted	14	(£0.93)	(£0.75)

There are no items of other comprehensive income, therefore profit/(loss) after taxation is the total comprehensive income attributable to shareholders.

All items in the above statement are derived from continuing operations.

Statement of Financial Position

as at 31 March 2023

	Notes	2023 £	2022 £
Non-current assets			
Listed investments at fair value through profit or loss			
(Cost - £159,575,223 (2022 - £157,707,331))		183,259,163	199,552,913
Unlisted investments at fair value through profit or loss			
(Cost - £13,110,193 (2022 - £5,268,633))		9,781,348	9,334,963
	10	193,040,511	208,887,876
Current assets			
Cash and cash equivalents		15,591,410	10,624,762
Amounts due from brokers		-	150,753
Dividends receivable		123,500	128,600
Interest receivable		7,389	-
Prepayments		10,107	2,373
		15,732,406	10,906,488
Total assets		208,772,917	219,794,364
Current liabilities			
Other payables and accrued expenses		(362,852)	(385,342)
Amounts due to brokers		(1,977,187)	-
		(2,340,039)	(385,342)
Net assets		206,432,878	219,409,022
Shareholders' equity			
Share capital	11	49,693,283	49,693,283
Other reserves		156,739,595	169,715,739
Total shareholders' equity		206,432,878	219,409,022
NAV per Ordinary Share	13, 14	£14.75	£15.67

The financial statements on pages 50 to 72 were approved by the Board on 5 July 2023 and are signed on its behalf by:

Jamie Brooke Gavin Farrell
Director Director

Statement of Changes in Equity

for the year ended 31 March 2023

	Notes	Share capital £	Capital redemption reserve £	Other reserves £	Total £
Balance at 1 April 2022	4	9,693,283	-	169,715,739	219,409,022
Total comprehensive loss for the year		-	-	(12,976,144)	(12,976,144)
Balance at 31 March 2023	49	,693,283	-	156,739,595	206,432,878

	Notes	Share capital £	Capital redemption reserve £	Other reserves £	Total £
Balance at 1 April 2021		49,705,783	-	180,605,540	230,311,323
Total comprehensive loss for the year		-	-	(10,490,201)	(10,490,201)
Transactions with owners, recorded directly in equity					
Contributions, redemptions and distributions					
to shareholders:					
- Share repurchase	11, 12	(12,500)	-	(399,600)	(412,100)
Balance at 31 March 2022		49,693,283	-	169,715,739	219,409,022

Statement of Cash Flows

for the year ended 31 March 2023

	Notes	2023 £	2022 £
Cash flows from operating activities			
Total loss for the year before taxation		(12,966,902)	(10,416,253)
Adjustments to reconcile total comprehensive loss to net cash flows:			
- Net realised gains on investments	10	(10,606,874)	(35,907,323)
- Unrealised losses on investments	10	25,556,817	44,145,402
- Net losses on foreign currency translation		878	28,860
Purchase of financial assets designated at fair value through profit or	loss1	(29,108,479)	(69,486,653)
Proceeds from sale of financial assets designated at fair value			
through profit or loss ²		32,133,841	76,880,915
Changes in working capital			
Decrease in dividends receivable ³		5,100	90,900
(Increase)/decrease in prepayments		(7,734)	13,735
Increase in interest receivable		(7,389)	-
(Decrease)/increase in other payables and accrued expenses		(22,490)	6,431
Withholding tax paid on dividends		(9,242)	(9,748)
Stamp duty tax paid		-	(64,200)
Net cash generated from operating activities		4,967,526	5,282,066
Cash flow from financing activities			
Share repurchase	11, 12	-	(412,100)
Net cash used in financing activities		-	(412,100)
Net increase in cash and cash equivalents		4,967,526	4,869,966
Cash and cash equivalents at the beginning of the year		10,624,762	5,783,656
Effect of exchange rate fluctuations on cash and cash equivalents		(878)	(28,860)
Cash and cash equivalents at the end of the year		15,591,410	10,624,762

^{1 -} Payables outstanding at 31 March 2023 relating to purchases of financial assets designated at fair value through profit amounted to £1,977,187 (2022: £nil).

^{2 -} Receivables outstanding at 31 March 2023 relating to sales of financial assets designated at fair value through profit amounted to £nil (2022: £150,753).

^{3 -} For the year ended 31 March 2023, cash received from dividends net withholding taxes was £4,846,320 (2022: £2,141,551)

Notes to the Financial Statements

1. General

The Company was registered in Guernsey on 2 December 1994 and commenced activities on 3 March 1995. The Company was listed on the London Stock Exchange on 3 March 1995.

The Company is a Guernsey Authorised Closed-Ended Investment Scheme, pursuant to the Protection of Investors (Bailiwick of Guernsey) Law 2020 and is subject to the Authorised Closed-Ended Investment Schemes Rules and Guidance, 2021.

The investment activities of the Company are managed by Harwood Capital Management (Gibraltar) Limited (the "Investment Manager") and the administration of the Company is delegated to the Administrator.

Legislation in Guernsey governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

2. Accounting policies

a) Basis of preparation

The financial statements of the Company, which give a true and fair view, and comply with the Companies (Guernsey) Law, 2008 (the "Law"), have been prepared in accordance with International Financial Reporting Standards ("IFRS"), as adopted by the UK. This comprises standards and interpretations approved by the International Accounting Standards Board, and International Accounting Standards and Standing Interpretations Committee interpretations approved by the International Accounting Standards Committee that remain in effect.

The financial statements have been prepared on the historical cost basis except for the inclusion at fair value of certain financial instruments. The principal accounting policies are set out below.

New standards, amendments and interpretations

There were no new standards, amendments or interpretations that are effective for the financial year beginning 1 April 2022 which the Directors consider to have a material impact on the financial statements of the Company.

2. Accounting policies (continued)

Standards, amendments and interpretations issued but not yet effective
Standards that become effective in future accounting periods and have not been adopted by the Company:

Inte	rnational Financial Reporting Standards (IFRS)	Effective for periods beginning on or after
•	IFRS 17 Insurance Contracts	1 January 2023
•	Amendments to IFRS 17	1 January 2023
•	Disclosure of Accounting Policies (Amendments to IAS 1 and IFRS Practice Statement 2)	1 January 2023
•	Definition of Accounting Estimate (Amendments to IAS 8)	1 January 2023
•	Deferred Tax Related to Assets and Liabilities Arising from a Single Transaction -	
	Amendments to IAS 12 Income Taxes	1 January 2023
•	Initial Application of IFRS 17 and IFRS 9 - Comparative Information (Amendments to IFRS 17)	1 January 2023
•	Classification of liabilities as current or non-current (Amendments to IAS 1)	1 January 2024
•	Lease Liability in a Sale and Leaseback (Amendments to IFRS 16)	1 January 2024
•	Non-current Liabilities with Covenants (Amendments to IAS 1)	1 January 2024
•	Sale or Contribution of Assets between an Investor and its Associate or Joint Venture	
	(Amendments to IFRS 10 and IAS 28)	Optional

The Directors do not believe that the application of the above amendments will have a material impact on the Company's financial statements.

A number of amendments and interpretations to existing standards have been issued, but are not yet effective, that are not relevant to the Company's operations. The Directors believe that the application of these amendments and interpretations will not materially impact the Company's financial statements when they become effective.

b) Going concern

Going concern refers to the assumption that the Company has the resources to continue in operation for the next 12 months from the date of approval of these financial statements. After analysing the following, the Directors believe that it is appropriate to adopt the going concern basis in preparing these financial statements:

- Working capital as at 31 March 2023, there was a working capital surplus of £13,392,367 (2022: £10,521,146).
- Closed-ended Company The Company has been authorised by the Guernsey Financial Services Commission as an Authorised Closed-ended Collective Investment Scheme, as such there cannot be any shareholder redemptions, and therefore no cash flows out of the Company in this respect. The cash position of the Company as at 31 March 2023 is £15,591,410 (2022: £10,624,762) which can sufficiently cover annual operating expenses, investment management fees and finance costs amounting to £2,963,587 for the year ended 31 March 2023 (2022: £4,209,713).
- Investments The Company has a tradable portfolio, as 95% of the investments, amounting to £183,259,163 as at 31 March 2023 (2022: £199,552,913) are listed and can therefore be readily sold for cash.

2. Accounting policies (continued)

Under Article 51 of the Articles of Incorporation, the Directors shall give due notice of and propose or cause to be proposed a special resolution that the Company be wound up at the Annual General Meeting ("AGM") of the Company every two years. The next notice will be given in the 2023 AGM documents (the previous notice was given at the 2021 AGM where the special resolution was not passed) where the Board will recommend that shareholders vote against resolution. The Directors, based on discussions with the Company's most significant shareholder, have a reasonable expectation that the special resolution outlined in Article 51 of the Articles of Incorporation and under "Life of the Company" will not be passed at the AGM in 2023.

Based on the above assessments, the Directors are of the opinion that the Company is able to meet its liabilities as they fall due for payment because it has and is expected to maintain adequate cash resources. Given the nature of the Company's business, the Directors have a reasonable expectation that the Company has adequate financial resources to continue in operational existence for the next 12 months from the date of approval of these financial statements. Therefore, the Board consider it appropriate to adopt the going concern basis in preparing the financial statements.

In making this assessment, the Board has considered the impact of the war in Ukraine, inflation, rising rates and supply chain disruptions on the Company and are confident that it remains appropriate to adopt the going concern basis.

c) Use of estimates and judgements

The preparation of financial statements in accordance with IFRS as adopted by the UK requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. These estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may vary from these estimates.

Judgement is exercised in terms of whether the price of recent transaction remains the best indicator of fair value for financial instruments at the statement of financial position date.

The Investment Manager reviews sector and market information and the circumstances of the investee Company to determine if the valuation adopted at the statement of financial position date remains the best indicator of fair value. The estimates and underlying assumptions are reviewed on an on-going basis.

Revisions to accounting estimates are recognised in the period in which the estimate is revised and reassessed every year to ensure the fair value remains appropriate. Information about areas of critical judgements in applying accounting policies that have the most significant effect on the fair value of financial instruments recognised in the financial statements are set out in note 2(e). Information about significant areas of estimation uncertainty that have the most significant effects on the fair value of financial instruments recognised in the financial statements are set out in notes 16 and 17.

d) Dividend income

Dividend income is recognised when the right to receive income is established. This is the ex-dividend date for equity securities. All income is shown gross of any applicable withholding tax.

2. Accounting policies (continued)

e) Financial assets

Classification

All investments of the Company are designated as financial assets at fair value through profit or loss. The investments are purchased mainly for their capital growth and the portfolio is managed, and performance evaluated, on a fair value basis in accordance with the Company's documented investment strategy, therefore the Directors consider that this is the most appropriate classification.

Recognition and subsequent measurement

Financial assets are measured initially at fair value being the transaction price. Subsequent to initial recognition on trade date, all assets classified at fair value through profit or loss are measured at fair value with changes in their fair value recognised in the Statement of Comprehensive Income. Transaction costs are separately presented in the Statement of Comprehensive Income.

Fair value measurement principles

Listed investments have been valued at the bid market price ruling at the reporting date. In the absence of the bid market price, the closing price has been taken, or, in either case, if the market is closed on the financial reporting date, the bid market or closing price on the preceding business day.

Fair value of unlisted investments is derived in accordance with the International Private Equity and Venture Capital (IPEV) valuation guidelines. Their valuation includes all factors that market participants would consider in setting a price. The primary valuation techniques employed to value the unlisted investments are earnings multiples and the net asset basis. Cost (as indicator of initial fair value) may be considered appropriate in the early stages of the investment, typically within one year.

The carrying amounts of Company's financial instruments, including cash and cash equivalents, dividends receivable, interest receivable and amounts due from brokers, approximate fair value due to their immediate or short-term maturity.

Derecognition

Derecognition of financial assets occurs when the rights to receive cash flows from financial instruments expire or are transferred and substantially all of the risks and rewards of ownership have been transferred. When an investment is derecognised, the unrealised gain or loss are recognised in the Statement of Comprehensive Income.

Fair value hierarchy

Fair value measurement should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering market participant assumptions, IFRS 13 - "Fair Value measurement", establishes a fair value hierarchy that gives the highest priority to unadjusted quoted prices in active markets (Level 1) and lowest priority to unobservable inputs (Level 3). The three levels of the value hierarchy are as follows:

Level 1: Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date;

Level 2: Inputs reflect quoted prices of similar assets and liabilities in active markets and quoted prices of identical assets and liabilities in markets that are considered to be inactive, as well as inputs other than quoted prices within Level 1 that are observable for the asset or liability either directly or indirectly; and

2. Accounting policies (continued)

Level 3: Inputs that are unobservable for the asset or liability and reflect the Investment Manager's own assumptions in accordance with the accounting policies disclosed within note 2 to the financial statements.

f) Prepayments

Prepayments do not carry any interest and are short term in nature and are accordingly stated at their amortised cost.

g) Cash and cash equivalents

Cash and cash equivalents consist of cash in hand and short term deposits in banks with original maturities of less than three months.

h) Foreign currency translation

Items included in the Company's financial statements are measured using the currency of the primary economic environment in which it operates (the "functional currency"). This is Pound Sterling (GBP) which reflects the Company's activity of investing in predominantly Sterling securities. The Company's shares are also issued in Pound Sterling (GBP). Foreign currency monetary assets and liabilities have been translated at the exchange rates ruling at the statement of financial position date. Transactions in foreign currency during the period have been translated into Pound Sterling (GBP) at the spot exchange rate in effect at the date of the transaction. Realised and unrealised gains and losses on currency translation are recognised in the Statement of Comprehensive Income.

i) Realised and unrealised gains and losses

Realised gains and losses arising on the disposal of investments are calculated by reference to the cost attributable to those investments and the sales proceeds, and are included in profit or loss in the Statement of Comprehensive Income. The change in unrealised gains and losses arising on investments held at the financial reporting date are also included in the Statement of Comprehensive Income. The cost of investments partly disposed is determined using the weighted average method.

j) Financial liabilities

Financial liabilities include other payables and accrued expenses, amounts due to brokers and amounts due on redemption of Ordinary Shares. Amounts due to brokers represent payables for investments that have been contracted for but not yet settled or delivered at the year end.

Financial liabilities are recognised initially at fair value, net of transaction costs incurred and are subsequently carried at amortised cost using the effective interest rate method. Financial liabilities are derecognised when the obligation specified in the contract is discharged, cancelled or expires.

k) Equity

Share capital represents the nominal value of equity shares and the excess of the paid up capital over the nominal value. Other reserves and the capital redemption reserve include all current and prior results as disclosed in the Statement of Comprehensive Income and the effect of share repurchases. Other reserves also include the deduction for the excess of consideration paid over nominal value on share buybacks.

2. Accounting policies (continued)

Expenses

Expenses are recognised in the Statement of Comprehensive Income upon utilisation of the service or at the date they are incurred.

m) Segmental reporting

Operating segments are reported in the manner consistent with the internal reporting used by the chief operating decision-maker ('CODM'). The CODM, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the Board who makes strategic decisions regarding the investments of the Company on an aggregated basis. Strategic and financial management decisions are determined centrally by the Board and, on this basis, the Company operates as a single investment management business and no segmental reporting is provided. Other than as disclosed in note 15, the CODM does not consider necessary to provide further analysis for the Company.

3. Income

	2023 £	2022 £
Dividends	4,850,462	2,060,399

4. Investment Manager's fee

In line with the Alternative Investment Fund Management Agreement, dated 1 October 2019, the Investment Manager is entitled to an annual fee of 1.25% on the first £15 million of the NAV of the Company, and 1% of any excess, payable monthly in arrears. Additionally, the Investment Manager is also entitled to an annual administration fee of £65,000 (2022: £61,000). The agreement can be terminated giving 12 months' notice or immediately should the Investment Manager be placed into receivership or liquidation. The Investment Manager is entitled to all the fees accrued and due up to the date of such termination but is not entitled to compensation in respect of any termination.

The fees incurred for the year ended 31 March 2023 were £2,156,129 (2022: £2,559,302) and as at the reporting date an amount of £181,269 was still payable to the Investment Manager (2022: £193,516). This amount is included in other payables and accrued expenses.

5. Directors' fees and expenses

Each Director is entitled to a fee of £20,000 per annum, the Chairman is entitled to an additional fee of £7,500 and the Audit Committee Chairman is entitled to an additional fee of £5,000. In addition, all Directors are entitled to reimbursement of travel, hotel and other expenses incurred by them in course of their duties relating to the Company. The Directors' fees and expenses due for the year ended 31 March 2023 are £152,500 (2022: £152,500) and as at 31 March 2023 an amount of £38,125 (2022: £38,125) was still payable to the Directors. This amount is included in other payables and accrued expenses.

6. Supplementary management fee

During a meeting of the Board on 8 December 2022, a payment of £100,000 (2022: £420,000) was recommended by the Chairman in respect of the 2022 Supplementary management fee. This was approved by the Board on 8 December 2022 and paid on 16 December 2022. The Board considers the payment of a Supplementary management fee annually based on the performance of the Company. The recognition and subsequent payment of this fee is at the discretion of the Board.

7. Administration fees

Administrator of the Company is appointed as secretary and administrator and is entitled to an annual fixed fee of £170,000 per annum as per the revised fee schedule signed in November 2019. The fees due for the year ended 31 March 2023 are £170,000 (2022: £170,000) and as at the reporting date an amount of £42,500 (2022: £42,500) was still payable to the Administrator. This amount is included in other payables and accrued expenses.

8. Custodian fees

The Administrator of the Company is appointed as custodian and is entitled to an annual safekeeping fee fixed at £30,000 per annum as per the revised fee schedule signed in November 2019. The fees due for the year ended 31 March 2023 are £30,000 (2022: £30,000) and as at the reporting date an amount of £7,500 was still payable to the custodian (2022: £7,500). This amount is included in other payables and accrued expenses.

9. Taxation

The Company is eligible for exemption from taxation in Guernsey under the provisions of the Income Tax (Exempt Bodies) (Guernsey) Ordinance, 1989. As such, the Company is only liable to pay a fixed annual fee, currently £1,200 (2022: £1,200). The withholding tax of £9,242 (2022: £9,748) in the Statement of Comprehensive Income relates to overseas dividends received or receivable and is irrecoverable.

10. Investments at fair value through profit or loss

The following table summarises the changes in fair value of the Company's listed equities for the year ended 31 March 2023.

	2023 £	2022 £
Cost at the beginning of the year	154,062,672	125,444,828
Opening unrealised gains	45,490,241	92,777,898
Fair value at 1 April	199,552,913	218,222,726
Net realised gains on investments	6,043,411	31,485,406
Unrealised (losses)/gains on investments	(21,806,301)	(47,287,657)
Disposals	(25,573,655)	(63,994,769)
Additions	30,642,795	66,047,010
Transfers	(5,600,000)	(4,919,803)
Fair value at end of the year	183,259,163	199,552,913
Cost at the end of the year	159,575,223	154,062,672
Unrealised gains at the end of the year	23,683,940	45,490,241
	183,259,163	199,552,913

10. Investments at fair value through profit or loss (continued)

The following table summarises the changes in fair value of the Company's unlisted equities and debt for the year ended 31 March 2023.

	2023 £	2022 £
Cost at the beginning of the year	8,913,292	4,974,291
Opening unrealised gain	421,671	2,676,472
Fair value at 1 April	9,334,963	7,650,763
Net realised gains on investments	4,563,464	4,421,918
Unrealised (losses)/gains on investments	(3,750,516)	3,098,143
Disposals	(6,409,433)	(12,864,339)
Additions	442,870	2,108,675
Transfers	5,600,000	4,919,803
Fair value at end of the year	9,781,348	9,334,963
Cost at the end of the year	13,110,193	8,913,292
Unrealised gains at the end of the year	(3,328,845)	421,671
	9,781,348	9,334,963

During 2023, GYG plc and Source Bioscience International plc, valued at £3,250,644 and £2,300,000 respectively (2022: £2,850,000 and £2,750,000) were delisted.

During 2022, Trellus Health Plc valued £950,000 (2021: £379,636) became listed on the London Stock Exchange ("LSE"). Studio Retail Group valued at £nil (2021: £423,750) went into administration and was thus suspended from the LSE. Mind Plus Machines Group Limited valued at £644,201 (2021: £1,755,000) and Urban Exposure Plc valued at £135,000 (2021: £3,120,689) went into liquidation during the year and were thus delisted.

11. Share capital

Authorised Share capital

	Number of Shares	£
Authorised:		
Ordinary Shares of 50p each	90,000,000	45,000,000
Ordinary Shares - 1 April 2022 to 31 March 2023 Ordinary Shares of 50p each		
	Number of Shares	Share capital £
At 1 April 2022	14,000,000	49,693,283
At 31 March 2023	14,000,000	49,693,283
Ordinary Shares - 1 April 2021 to 31 March 2022 Ordinary Shares of 50p each		
	Number of Shares	Share capital £
At 1 April 2021	14,025,000	49,705,783
Share repurchase	(25,000)	(12,500
At 31 March 2022	14,000,000	49,693,283

Rights attributable to Ordinary Shares

In a winding-up, the holders of Ordinary Shares are entitled to the repayment of the nominal amount paid up on their shares. In addition, they have the right to receive surplus assets available for distribution. The shares confer the right to dividends, and at general meetings, on a poll, confer the right to one vote in respect of each Ordinary Share held.

12. Share buybacks

In accordance with section 315 of the Law, the Company has been granted authority to make one or more market acquisitions (as defined in section 316 of the Law, of Ordinary Shares of 50 pence each in the capital of the Company (the "Ordinary Shares") on such terms and in such manner as the Directors of the Company may from time to time determine, provided that:

- a) the maximum aggregate number of Ordinary Shares authorised to be acquired does not exceed 10 per cent. of the issued Ordinary Share capital of the Company on the date the shareholders' resolution is passed;
- b) the minimum price (exclusive of expenses) payable by the Company for each Ordinary Share is 50 pence. The maximum price payable by the Company for each Ordinary Share is an amount equal to 105 per cent of the average of the middle market quotations for an Ordinary Share which is derived from The London Stock Exchange Daily Official List for the five business days immediately preceding the day on which that Ordinary Share is purchased and that stipulated by Article 5(1) of the Buyback and Stabilisation Regulation being the higher of the price of the last independent trade and the highest current independent bid available in the market;

12. Share buybacks (continued)

- c) subject to paragraph (d), this authority shall expire (unless previously renewed or revoked) at the earlier of the conclusion of the next annual general meeting of the Company or on the date which is 18 months from the date of the previous shareholders' resolution;
- d) notwithstanding paragraph (c), the Company may make a contract to purchase Ordinary Shares under the authority from the shareholders' before its expiry which will or may be executed wholly or partly after the expiry of the authority and may make a purchase of Ordinary Shares in pursuance of any such contract after such expiry; and
- e) the price payable for any Ordinary Shares so purchased may be paid by the Company to the fullest extent permitted by the Law.

A renewal of the authority to make purchases of the Company's own Ordinary Shares will be sought from existing shareholders at each annual general meeting of the Company.

Between 1 April 2022 and 31 March 2023, the Company did not carry out any share buybacks. Between 1 April 2021 and 31 March 2022, the Company carried out two share buybacks, resulting in a total reduction of 25,000 shares for a cost of £412,100. These shares were subsequently cancelled.

13. Reconciliation of NAV to published NAV

	202	2023		2022	
	£	£ per share	£	£ per share	
Published NAV	209,498,295	14.97	223,906,248	15.99	
Unrealised loss on revaluation of investments at bid / mid-price	(3,065,417)	(0.22)	(4,497,226)	(0.32)	
NAV attributable to shareholders	206,432,878	14.75	219,409,022	15.67	

The published monthly NAV is produced within 15 working days of the month end and values the listed investments at midprice. The financial statements value listed investments at their bid price.

14. Loss per Ordinary Share and NAV per Ordinary Share

The calculation of basic loss per Ordinary share of £0.93 (2022: loss per Ordinary share of £0.75) is based on net loss of £12,976,144 (2022: net loss of £10,490,201) and the weighted average number of shares in issue during the year of 14,000,000 shares (2022: 14,014,151 shares). At 31 March 2023 there was no difference in the basic and diluted loss per Ordinary share calculation.

The calculation of NAV per Ordinary Share of £14.75 (2022: £15.67) is based on a NAV of £206,432,878 (2022: £219,409,022) and the number of shares in issue at the year-end of 14,000,000 shares (2022: 14,000,000 shares).

15. Segment information

The Chief Operating Decision Makers ("CODM") of the Company are the Board. The Company has one reportable segment. The Board reviews internal management reports on a quarterly basis.

Information on realised gains and losses derived from sales of investments are disclosed in note 10 to the financial statements.

The Company is domiciled in Guernsey. All of the Company's income from investments is from underlying companies. The majority of these companies are incorporated in countries other than Guernsey (mainly Great Britain).

The geographical breakdown of the Company's investment portfolio is set out on pages 8 to 10 of the Annual Report.

The Company has no non-financial assets classified as non-current assets. Shareholders with holdings of 5% or more are disclosed on page 17 of the Annual Report.

16. Financial risk management

The main risks arising from the Company's activities are:

- (i) market risk, including currency risk, interest rate risk and other price risk;
- (ii) liquidity risk; and
- (iii) credit risk

The Company Secretary, in close co-operation with the Board and the Investment Manager, coordinates the Company's risk management. The policies for managing each of these risks are summarised below and have been applied throughout the year.

i) Market risk

The fair value of future cash flows of a financial instrument held by the Company may fluctuate because of changes in market prices. This market risk comprises currency risk, interest rate risk and other price risk. The Board reviews and agrees policies for managing these risks.

Currency risk

The functional and presentation currency of the Company is Pound Sterling (GBP) and, therefore, the Company's principal exposure to foreign currency risk comprises investments priced in other currencies, principally US Dollars. The Investment Manager monitors the Company's exposure to foreign currencies and reports to the Board on a regular basis. The Investment Manager measures the risk to the Company of the foreign currency exposure by considering the effect on the NAV and income of a movement in the rates of exchange to which the Company's assets, liabilities, income and expenses are exposed.

16. Financial risk management (continued)

At 31 March 2023 the currency profile of those financial assets and liabilities was:

	GBP £	EUR £	USD £	Total £
Investments at fair value through profit or loss	190,586,806	-	2,453,705	193,040,511
Dividends receivable	123,500	-	-	123,500
Amounts due to brokers	(1,977,187)	-	-	(1,977,187)
Cash and cash equivalents	15,591,410	-	-	15,591,410
Trade and other payables	(362,852)	-	-	(362,852)
Total net foreign currency exposure	203,961,677	-	2,453,705	206,415,382

At 31 March 2022 the currency profile of those financial assets and liabilities was:

	GBP £	EUR £	USD £	Total £
Investments at fair value through profit or loss	203,631,209	-	5,256,667	208,887,876
Dividends receivable	128,600	-	-	128,600
Amounts due from brokers	150,753	-	-	150,753
Cash and cash equivalents	10,622,128	-	2,634	10,624,762
Trade and other payables	(385,342)	-	-	(385,342)
Total net foreign currency exposure	214,147,348	-	5,259,301	219,406,649

Sensitivity analysis is based on the Company's monetary foreign currency instruments held at each balance sheet date. A 10% change in the exchange rate is considered reasonable based on observation of current market conditions.

Currency	Change in the exchange rate	31 March 2023 Impact on Total Comprehensive Impact on Income Net Assets £ £		31 March 2022 Impact on Total Comprehensive Impac Income Net As		
USD vs GBP	10%/(10%)	(223,064)/272,634	(223,064)/272,634	(477,879)/584,074	(477,879)/584,074	

Interest rate risk

Interest rate movements may affect:

- the fair value of the investments in fixed rate securities;
- the level of income receivable on cash deposits and floating rate debt instruments; and the interest payable on the Company's variable rate borrowings, if any.

The possible effects on fair value and cash flows that could arise as a result of changes in interest rates are taken into account when making investment decisions and borrowings, if any. The Board reviews on a regular basis the values of the unquoted loans and preferred shares to companies in which private equity investment is made. Interest rate risk is not significant to the Company as it has no significant fixed income investments or borrowings.

16. Financial risk management (continued)

Other price risk

Other price risks (i.e. changes in market prices other than those arising from currency risk or interest rate risk) may affect the value of investments.

The Company's exposure to price risk comprises mainly of movements in the value of the Company's investments. As at the year-end, the spread of the Company's investment portfolio is detailed on pages 8 to 10.

The Board manages the market price risks inherent in the investment portfolio by ensuring full and timely access to relevant investment information from the Investment Manager. The Board meets regularly and at each meeting reviews investment performance. The Board monitors the Investment Manager's compliance with the Company's objectives and is directly responsible for investment strategy and asset allocation.

The Company's exposure to other changes in market prices at 31 March 2023 on its investments was as follows:

	2023 £	2022 £
Financial assets at fair value through profit or loss		
- Non-current investments at fair value through profit or loss	193,040,511	208,887,876

The following table illustrates the sensitivity of the profit and net assets to an increase or decrease of 15% (2022:15%) in the fair values of the Company's investments. This level of change is considered to be reasonably possible based on observation of current market conditions. The sensitivity analysis is based on the Company's investments at each balance sheet date, with all other variables held constant.

	20	23	2022		
	Increase in fair value £	Decrease in fair value £	Increase in fair value £	Decrease in fair value £	
Statement of Comprehensive Income					
Profit/(loss) for the year	28,956,077	(28,956,077)	31,333,181	(31,333,181)	
Net assets	28,956,077	(28,956,077)	31,333,181	(31,333,181)	

ii) Liquidity risk

This is the risk that the Company will encounter difficulty in meeting obligations associated with financial liabilities.

The Company is faced with some level of liquidity risk as 5.07% (2022: 4.25%) of the Company's investments are in unlisted equities and other investments that may not be readily realisable.

In accordance with the Company's policy, the Investment Manager monitors the Company's liquidity risk, and the Board has overall responsibility.

16. Financial risk management (continued)

The table below shows the split of investments with maturity dates of less than a year and investments with no maturity date

	Less than 1 year £	31 March Greater than 1 year £	n 2023 No maturity date £	Total £	Less than 1 year £	31 Marci Greater than 1 year £	n 2022 No maturity date £	Total £
Listed	-	-	183,259,163	183,259,163	-	-	199,552,913	199,552,913
Unlisted	-	-	9,781,348	9,781,348	-	-	9,334,963	9,334,963
	-	-	193,040,511	193,040,511	-	-	208,887,876	208,887,876

The Company's financial liabilities are due to mature within one year from the Statement of Financial Position date. The contractual maturities of these financial liabilities equal their carrying amount on the Statement of Financial Position. As the Company is in a net current asset position, the Directors are satisfied that there are adequate resources to meet these obligations as they fall due.

iii) Credit risk

The Company does not have any significant exposure to credit risk arising from any one individual party. Credit risk is spread across a number of counterparties, each having an immaterial effect on the Company's cash flows, should a default happen. The Company's maximum credit risk exposure at the Statement of Financial Position date is represented by the respective carrying amounts of the financial assets in the Statement of Financial Position.

There is a risk that the custodian and bank used by the Company to hold assets and cash balances could fail and that the Company's assets may not be returned.

Associated with this is the additional risk of fraud or theft by employees of those third parties. The Board manages this risk through the Investment Manager monitoring the financial position of those custodians and banks used by the Company.

The credit rating of the custodian and the bank, BNP Paribas S.A., Guernsey Branch, is A-1 with Standard & Poor's.

iv) Operational risk

Operational risk is the risk of direct or indirect loss arising from a wide variety of causes associated with the processes, technology and infrastructure supporting the Company's activities with financial instruments either internally within the Company or externally at the Company's service providers, and from external factors other than credit, market and liquidity risks such as those arising from legal and regulatory requirements and generally accepted standards of investment management behaviour.

The Company's objective is to manage operational risk so as to balance limiting of financial losses and damage to its reputation with achieving its investment objective.

16. Financial risk management (continued)

Capital management policies and procedures

The Company's capital management objectives are:

- to ensure that the Company will be able to continue as a going concern; and
- to maximise the income and capital return to its equity shareholders through an appropriate balance of equity capital and long-term debt. The policy is that gearing should not exceed 20% of net assets.

The Company's capital at 31 March 2023 comprises:

	2023 £	2022 £
Equity		
Share capital	49,693,283	49,693,283
Other reserves	156,739,595	169,715,739
	206,432,878	219,409,022

The Company does not have any long term debt outstanding as at 31 March 2023 and 31 March 2022.

The Board, with the assistance of the Investment Manager, monitors and reviews the broad structure of the Company's capital on an ongoing basis. This review includes:

- the planned level of gearing, which takes account of the Investment Manager's views on the market;
- the need to buy back equity shares for cancellation, which takes account of the difference between the NAV per share and the share price (i.e. the level of share price discount or premium);
- the need for new issues of equity shares; and
- the extent to which revenue in excess of that which is required to be distributed should be retained.

The Company's objectives, policies and processes for managing capital are unchanged from the preceding accounting period and there are no imposed capital requirements.

17. Fair value hierarchy

Where an asset or liability's value is determined based on inputs from different levels of the hierarchy, the level in the fair value hierarchy assumed for the valuation assessment is the lowest level input significant to the fair value measurement in its entirety.

Investments whose values are based on quoted market prices in active markets, and therefore classified within Level 1, include active listed equities. The Company does not adjust the quoted price for these instruments.

Financial instruments that trade in markets that are not considered to be active but are valued based on quoted market prices, dealer quotations or alternative pricing sources supported by observable inputs are classified within Level 2. As Level 2 investments include positions that are not traded in active markets and/or are subject to transfer restrictions, valuations may be adjusted to reflect illiquidity and/or non-transferability, which are generally based on available market information.

Investments classified within Level 3 have significant unobservable inputs. Level 3 instruments consists of private equity positions. As observable prices are not available for these securities, the Company has used valuation techniques to derive the fair value. For certain investments, the Company utilises comparable trading multiples and recent transactions in arriving at the valuation for these positions. The Investment Manager determines comparable public companies (peers) based on industry, size, developmental stage and strategy.

Management then calculates a trading multiple for each comparable Company identified. The multiple is calculated by dividing the enterprise value of the comparable Company by its earnings before interest, taxes, depreciation and amortisation ("EBITDA"). The trading multiple is then discounted for considerations such as illiquidity and differences between the comparable companies based on Company-specific facts and circumstances. New investments are initially carried at cost, for a limited period, being the fair value of the most recent investment in the investee Company.

In accordance with IPEV valuation guidelines, changes and events since the acquisition date are monitored to assess the impact on the fair value of the investment and the valuation derived from investment cost is adjusted if necessary. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

The table below analyses financial instruments measured at fair value at the end of the reporting period by the level in the fair value hierarchy into which the fair value measurement is categorised.

31 March 2023	Level 1 £	Level 2 £	Level 3 £	Total £
Financial assets at fair value				
through profit or loss				
Listed securities	183,259,163	-	-	183,259,163
Unlisted securities	-	-	9,781,348	9,781,348
	183,259,163	-	9,781,348	193,040,511

17. Fair value hierarchy (continued)

31 March 2022	Level 1 £	Level 2 £	Level 3 £	Total £
Financial assets at fair value				
through profit or loss				
Listed securities	199,552,913	-	-	199,552,913
Unlisted securities	-	-	9,334,963	9,334,963
	199,552,913	-	9,334,963	208,887,876

The following table summarises the changes in fair value of the Company's Level 3 investments for the year ended 31 March 2023.

	2023 £	2022 £
Balance at 1 April	9,334,963	7,650,763
Net realised gains on investments	4,563,464	4,421,918
Unrealised (losses)/gains on investments	(3,750,516)	3,098,143
Sale of investments	(6,409,433)	(12,864,339)
Purchase of investments	442,870	2,108,675
Transfers between levels	5,600,000	4,919,803
Balance at 31 March	9,781,348	9,334,963

Transfers between levels are determined based on changes to the significant inputs used in the fair value estimation. Any transfers between levels, in the fair value hierarchy, are recognised at the beginning of the relevant reporting period.

During 2023, GYG plc and Source Bioscience International plc, valued at £3,250,644 and £2,300,000 respectively (2022: £2,850,000 and £2,750,000) were delisted and thus, transferred from Level 1 to Level 3.

During 2022, Trellus Health Plc valued £950,000 became listed on the LSE and thus transferred from Level 1 to Level 3. Studio Retail Group valued at £nil went into administration and was thus suspended from the LSE. Mind Plus Machines Group Limited valued at £644,201 and Urban Exposure Plc valued at £135,000 went into liquidation during the year and were thus delisted and transferred from Level 1 to Level 3.

17. Fair value hierarchy (continued)

The table below sets out sensitivity to the earnings multiples used at 31 March 2023 in measuring a significant investment categorised as Level 3 in the fair value hierarchy and measured based on comparable multiples approach.

Valuation Method	Fair Value at 31 March 2023 (£)	Unobservable inputs	Factor	Sensitivity to changes in significant unobservable inputs
Comparable Company Multiples	2,276,973	Earnings (EBITDA) multiple	7.0x	The estimated fair value would increase if: - the Earnings (EBITDA) multiple was changed
Valuation Method	Fair Value at 31 March 2022 (£)	Unobservable inputs	Factor	Sensitivity to changes in significant unobservable inputs
Comparable Company Multiples	2,351,230	Earnings (EBITDA) multiple	6.7x	The estimated fair value would increase if: - the Earnings (EBITDA) multiple was changed

The remaining investments classified as Level 3 have not been included in the above analysis as they have either a fair value that either approximates a recent transaction price or is cash held in escrow pending the outcome of certain post sale conditions (i.e. warranties).

Although the Company believes that its estimates of fair value are appropriate, the use of different methodologies or assumptions could lead to different measurements of fair value. For fair value measurements in Level 3, changing one or more of the assumptions used to reasonably possible alternative assumptions would have the following effects on the net assets attributable to the shareholders.

Input	Sensitivity used	£
Farnings (FRITDA)	+/- 10 0% (7 7/6 3)	267,929/(267,929)
3 \ , , ,	17 10.0% (7.770.3)	201,7271 (201,727)
mattiple		
Input	Sensitivity used	£
Earnings (EBITDA)	+/- 10.0% (7.4/6.0)	186,507/(186,507)
multiple	` '	, , , ,
	Earnings (EBITDA) multiple Input Earnings (EBITDA)	Earnings (EBITDA) +/- 10.0% (7.7/6.3) multiple Input Sensitivity used Earnings (EBITDA) +/- 10.0% (7.4/6.0)

A sensitivity of 1.0x and 10% has been considered appropriate given the earnings (EBITDA) multiple for comparable Company multiples lies within this range.

18. Related parties

All transactions with related parties are carried out at arm's length and the prices reflect the prevailing fair market value of the assets on the date of the transaction.

The Investment Manager are considered to be related parties. The fees paid are included in the Statement of Comprehensive Income and further detailed in notes 4 and 6.

The Directors are also considered related parties and their total fees during the year ended 31 March 2023 amounted to £152,500 (2022: £152,500). At 31 March 2023, £38,125 (2022: £38,125) included in other accruals and payables was payable to the Directors. Please refer to note 5 for further details.

Christopher Mills is a Director and shareholder of the Company. He is also a Director of the Company's Investment Manager and Chief Investment Officer of North Atlantic Smaller Companies Investment Trust plc ("NASCIT"), which is a substantial shareholder of the Company as detailed on page 17 and note 19 of the Annual Report.

Rupert Evans, who resigned as a Director of the Company on 15 September 2022 is a consultant to the law firm Mourant Ozannes, the legal adviser to the Company. The Company did not receive any legal services from Mourant Ozannes during the year, nor did it receive any services in the prior year.

Sidney Cabessa is a Director of Harwood Capital Management Limited, the parent Company of the Investment Manager. No fees were paid or are payable to Harwood Capital Management Limited.

19. Majority Shareholder

NASCIT holds 52.68% of the Ordinary shares of the Company.

20. Subsequent Events

There have been no significant events subsequent to the year end, which, in the opinion of the Directors, may have had an impact on the financial statements for the year ended 31 March 2023.

Alternative Performance Measures

NAV per Ordinary Share

NAV per Ordinary Share means an amount equal to, as at the relevant date, the NAV attributable to Ordinary Shares divided by the number of Ordinary Shares in issue as at such date.

Reason for use

Common industry performance benchmark for calculating the Total Return and Share Price (Discount)/Premium to NAV per Ordinary Share.

Recalculation

NAV per Ordinary Share is calculated as follows:

	31 March 2023	31 March 2022
Net Assets as per Statement of Financial Position	£206,432,878	£219,409,022
Number of Ordinary Shares in issue at year	14,000,000	14,000,000
NAV per Ordinary Share	£14.75	£15.67

Share Price Discount to NAV per Ordinary Share

Closing price as at such date as published on the London Stock Exchange divided by the NAV per Ordinary Share.

Reason for use

Common industry measure to understand the price of the Company's shares relative to its net asset valuation.

Recalculation

	31 March 2023	31 March 2022
Closing price as at 31 March as published on the London Stock Exchange	£11.95	£14.80
NAV per Ordinary Share	£14.75	£15.67
Share Price Discount	(18.98)%	(5.55)%

Company Information

Registered Office

BNP Paribas House, St Julian's Avenue, St Peter Port, Guernsey, GY1 1WA

Investment Manager

Harwood Capital Management (Gibraltar) Limited LLP Suite 827 Europort, Europort Road, Gibraltar

Custodian

BNP Paribas S.A., Guernsey Branch BNP Paribas House, St Julian's Avenue, St Peter Port, Guernsey, GY1 1WA

Secretary and Administration

BNP Paribas S.A., Guernsey Branch BNP Paribas House, St Julian's Avenue, St Peter Port, Guernsey, GY1 1WA

Registrars

Link Market Services (Guernsey) Limited PO Box 627, St Sampson, Guernsey, GY1 4PP

Stockbroker

Winterflood Securities Limited
The Atrium Building, Cannon Bridge House
25 Dowgate, Hill, London, EC4R 2GA

Independent Auditor

RSM CI (Audit) Limited P.O. Box 179, 40 Esplanade St Helier, Jersey, JE4 9RJ

Legal Advisers

To the Company as to Guernsey law:
Mourant Ozannes
Royal Chambers, St. Julian's Avenue, St Peter Port,
Guernsey, Channel Islands, GY1 4HP

To the Company as to English law:

Bircham Dyson Bell One Bartholomew CI London, EC1A 7BL

Website

www.oryxinternationalgrowthfund.co.uk

